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Abstract
I have conceived, undertaken and published a body of work in Urology which 
has applied an evidence-based approach to different aspects with widely 
varying success in modifying the impact on treatment choices and outcome.
On the positive side, the research work I have led has demonstrated that the 
era when death statistics could be used to the occurrence of benign prostatic 
hyperplasia was gone and that we had moved to an epoch where 
symptomatic disease and quality of life were the key issues [1-3]. I have 
worked on the creation of the questionnaire-based approach necessary for 
evaluating the presence of various urological conditions for use in different 
populations clearly identified [4-7] and quantified the extent and inter­
relationships between the various benign urological conditions in communities 
[8-21]. This work has made it quite clear that such benign conditions as 
benign prostatic hyperplasia, erectile dysfunction, incontinence, prostatitis and 
cystitis are remarkably common conditions world-wide in ageing populations.
Since 1990, treatment options for men with symptomatic BPH have moved 
from an essentially surgical approach to an increasing introduction of 
pharmacologic options and less invasive approaches to disease management. 
The meta-analysis of the Phase III clinical trials of finasteride which I 
undertook, demonstrated that this drug was effective only in men with 
enlarged prostates [22] and justified the biological approach taken in the 
development of this drug which was an inhibitor of 5-alpha reductase, the 
enzyme which converts Testosterone (T) to Dihydrotestosterone (DHT) the 
metabolite which made the prostate hyperplastic. I then demonstrated that 
serum PSA was a good indicator of prostate volume [23] thus making 
identification of men who would most likely respond to this drug easily 
identifiable [23, 24]. Using this same dataset, I was able to demonstrate that 
finasteride reduced the risk of Acute Urinary Retention (AUR) [25-26] and that 
it was superior to alpha-blockers, the other major class of drugs used to treat
symptomatic BPH, in this regard [27]. I designed the phase III trials of 
dutasteride, a new five-alpha reductase inhibitor, and the findings lay on the 
regression line demonstrated in the meta-analysis of finasteride [28] and also 
had the identical effect on reducing the risk of AUR. Finasteride and 
Doxasozin, an alpha-blocker, act separately in reducing symptoms of benign 
prostatic hyperplasia [30] and also AUR. I was able to develop a method of 
predicting individual risk of AUR in men who were diagnosed with benign 
prostatic hyperplasia [31].
In addition, I was able to demonstrated that (the alpha-blocker) terasozin was 
effective in reducing the symptoms of BPH and also to increasing peak urinary 
flow rate and that it appeared equally effective at all doses tried [33]. 
Permixon, a drug comprising an extract of seronoa repens, has also been 
widely employed in the treatment of symptomatic men and I was able to 
demonstrate that this was effective [34] and subsequently that it also 
significantly reduced the symptoms scores [35]. More recently, I was able to 
demonstrate in a meta-analysis the efficacy of Trans Urethral Needle Ablation 
(TUNA) therapy in reducing symptoms in men with severe symptoms and that 
this treatment appears to be equally effective as those obtained by trans­
urethral prostatectomy in similar groups of patients [36].
Overall, these findings have influenced clinical practice in benign prostatic 
hyperplasia in helping clarify what is the right treatment for a particular 
patient and this is reflected currently in international treatment guidelines 
[32].
I was able to demonstrate that in the Dialysis Registry of the Regione 
Lombardia in Italy that those patients who had been receiving renal 
replacement therapy, essentially renal dialysis, had an increased risk of certain 
specific types of cancer [38], In a certain sense, I used this as a pilot study 
and we were able to undertake a pooled analysis of the world's three leading 
Dialysis Registries, involving over 900,000 patients, dialysed but not
transplanted, followed up for cancer. There is a clear association with an 
increased risk of certain types of cancer [38-39] and also specific associations 
with certain types of renal disease underlying the reason for dialysis [40]. 
These results, which involved such a large proportion of the world experience 
with renal dialysis, cannot be repeated for many years and clearly 
demonstrates the need for a re-think regarding the associations and 
mechanisms thought to be specific between recipients of renal grafts and risk 
of certain cancers.
Looking at all the incidence and mortality data available world-wide, the 
importance of urological cancers as a Public Health issue is clear: such 
cancers account for over a quarter of all cancer in men [41]. Testicular cancer 
was once almost uniformly fatal but a new and highly effective treatment 
schedule, evolved around cis-platin, was presented around the mid-1970's. 
Following that, the effect could be seen at a national level where, in Scotland, 
while the incidence continued to risk the mortality rate was clearly falling 
quickly by the mid-1980s [42]. Fortunately, this was the case in all countries 
where data were available with the notable exceptions of those countries of 
Central and Eastern Europe, which at the time were members of the 
COMECON [43-44]. However, when a specialist, well funded central treatment 
facility was established In Bratislava (Slovakia) in 1983, the subsequent impact 
on mortality was remarkable even although Incidence continued to rise [45]. 
The most rapid economic change took place in the former German Democratic 
Republic {East Germanÿ) and the fall in testicular cancer mortality was almost 
immediate [46]. It is now clear that mortality from testicular cancer is 
declining while incidence is rising [48] although the rate of decline is less in 
countries of central and eastern Europe [47]. Eradicating testicular cancer as 
a cause of death should prove possible within our current knowledge: it is not 
a matter requiring successful research merely an economic and logistic issue 
[49].
I published 20 years ago that there was little change taking place in time 
trends of prostate cancer world-wide [50] although a rising incidence rate was 
apparent by the early 1990s [51] and mortality was not increasing [52]. At the 
same time, little is known about the aetiology of prostate cancer [53-54] 
despite high-quality and quite innovative aetiological studies [55-66].
This is a very disappointing situation and has contributed to the desire and 
the rush to find effective ways of finding the disease earlier when outcome 
appears to be much Improved [67]. I analysed data from the Tyrol Screening 
Study which clearly demonstrated that the mortality from prostate cancer 
declined following the introduction of a free-screening programme with PSA. 
This result was consistent with the hypothesis that a PSA screening 
programme, with a high uptake by the community and careful quality control, 
conducted in an area where all men had free access to high-quality 
diagnostics, urology and medical oncology could successfully reduce the 
mortality from prostate cancer [68-70]. Unfortunately, many men are being 
urged to have a PSA measured in areas where these circumstances do not 
apply. The overall net effect could well be a slight reduction in mortality offset 
by a large loss of quality-of-life in the community [71].
This evidence-based approach I have managed to create and undertake has 
resulted in major modifications to clinical practice in benign prostatic 
hyperplasia and this is represented in international treatment guidelines. 
Unfortunately, the decline in mortality from testicular cancer in Central and 
Eastern Europe is slower than I would have hoped and PSA screening for 
prostate cancer has become extremely prevalent among men without any 
secure data being available regarding its efficacy and in the absence of any 
widespread population-based evaluation of such screening strategy.
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1. Introduction
1. Benign Urological conditions such as Benign Prostatic Hyperplasia, 
Urinary Incontinence and Erectile Dysfunction are very common and 
affect large numbers of the ageing population. Although they are 
benign in the sense that they do not pose an increased risk of death, 
these conditions can frequently be malignant in terms of their impact of 
quality of life. Urological Cancers are also very common and constitute 
a large proportion of the global cancer burden.
2. The past decade has seen enormous progress made in the quality 
of research in Urology. The introduction of an evidence-based approach 
has proved to be enormously successful in certain areas, notably in 
men with symptomatic Benign Prostatic Hyperplasia in identifying the 
right patient for the right treatment. However, there have been certain 
notable failures in other domains such as Testicular Cancer and 
Prostate Cancer, particularly Prostate Cancer Screening.
3. In this thesis, I will outline my contribution in several of these 
areas, some of which could be considered successful in terms of 
changing clinical practice and In other areas where the approach has 
identified a situation where no positive change has taken place.
Benign Prostatic Hyperplasia Epidemiology
4. Urinary difficulties have presented problems to elderly men and 
their physicians dating back to antiquity. Despite its long history, BPH 
was not identified as a disease entity until the nineteenth century and it 
was only during the present century that effective treatment became 
available. Furthermore, only in the last decade has information 
regarding its epidemiology and natural history become available. This
information came originally from autopsy series and surgical series and 
it is only recently that better quality data have become available.
5. Benign Prostatic Hyperplasia (BPH) describes a proliferative process 
of both stromal and epithelial elements of the prostate which is 
characterised by progressive enlargement of the prostate gland which 
results in obstruction of the flow of urine from the bladder. The clinical 
manifestations commonly attributed to BPH include lower urinary tract 
symptoms, detrusor instability, incomplete bladder emptying, urinary 
retention and urinary tract infection.
6. Today it is common for men and women to live beyond 50 years 
but this is a common phenomenon only of this current century: 
research tells us that adaptation can take many centuries. With the 
twentieth century has come a wide range of diseases of affluence and 
aging, including appendicitis, myocardial infarction, osteoporosis and a 
range of urological disorders including cancers and a number of benign 
diseases notably Lower Urinary Tract Symptoms (LUTS) (frequently 
referred to as Benign Prostatic Hyperplasia (BPH)), Male Erectile 
Dysfunction (MED) and Urinary Incontinence (UI). Prior to age 40 these 
urological conditions are relatively uncommon but the prevalence rises 
such that the majority of men over 70 years of age may suffer from at 
least one of them and a large proportion of women. One hundred years 
ago this was of little consequence in Public Health terms, but today life 
expectancy approaches 80 years in the most developed countries. 
Urological cancers constitute over one-cancer in four in men and cause 
a large number of deaths world-wide each year. While most other 
urological conditions do not kill, they are major contributors to a 
reduced quality-of-life and the consequent psychological sequelae of 
many ageing people: although benign in nature, they are frequently 
malignant\w terms of their impact on quality-of-life.
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2.1 BPH Epidemiology circa 1990
7. A review I made of all the published epidemiological literature on 
Benign Prostatic Hyperplasia, published in 1991, came to some clear 
conclusions regarding the current situation and how to proceed [1]. 
The evidence base available was poor and fragmented and required 
strengthening. The estimates of occurrence were most frequently 
based on anecdote and, where quantified, based on autopsy series and 
death statistics. Virtually nothing was known about the aetiological 
determinants of BPH and all the available evidence was anecdotal. It 
was clear that both the Descriptive Epidemiology and the Analytical 
Epidemiology required to be strengthened since little was known to 
provide estimates of the prevalence of the condition in communities 
and prospects for prevention were exceedingly poor in the absence of 
knowledge of risk determinants.
8. Determination of disease frequency, the first step towards 
geographical and temporal comparisons, relies on a definition (or at 
least on a working epidemiological definition whose sensitivity and 
specificity are known) of the disease or condition under investigation. 
This has been a major problem with the common benign urological 
conditions (LUTS, MED and UI). Male erectile dysfunction shares with 
the other common urological condition of benign prostatic hyperplasia 
(BPH) the absence of a unifying definition, whose sensitivity and 
specificity can be determined.
2.2 Trends in M ortality from Benign Prostatic Hyperplasia
9. Benign Prostatic Hyperplasia has been a uniquely identified item in 
classifications of cause of death since early in the 20*^  century. 
Mortality data by cause are routinely available for many countries since 
1950 in the World Health Organisation Mortality Database and this was 
used to examine BPH. The mortality rate from BPH has been declining
11
appreciably in most developed countries [2], In the period 1950-1954, 
the highest mortality rate from BPH was 22.9 per 100,000 in Denmark, 
and 17 of 24 countries had a mortality rate greater than 10 per 
100,000. In 1985-89, data available from 61 countries showed that 
only one (Saint Vincent and the Grenadines) had a mortality rate 
greater than 10 per 100,000. The decline is most notable in developed 
western countries such as the United States, Canada, Australia, New 
Zealand and the countries of western Europe. The death rate has been 
decreasing more slowly in countries of central and eastern Europe and 
has stabilized recently. Rates in the former USSR, Byelorussian SSR 
and Ukrainian SSR, are still very high, but the only data available are 
for recent time periods, which exclude the examination of secular 
trends. High death rates are still observed in countries of South 
America and in a cluster of countries around the Caribbean with high 
mortality rates. Although the numbers of cases in many of these 
countries are small, the rates appear to have stabilized over time. For 
example, the death rates are still high in Trinidad at 6.8 per 100,000 
based on an average of 29 deaths per annum.
10. In the United States, the age-adjusted mortality rate fell from 7.5 
per 100,000 in 1950-54 to 0.3 per 100,000 in 1985-89. The age- 
adjusted relative risk of death in 1987 was only 6% of that in 1957. 
The largest declines have taken place in the older age groups. In 
absolute terms, this represents a decline from an average of 6,261 
deaths per annum in the period 1950-54 to 470 deaths per annum in 
1985-89, a saving of at least 5,791 lives each year. In the United 
Kingdom, the age-adjusted mortality rate fell from 16.5 to 1.2 per
100,000 during these time periods. The age-adjusted relative risk of 
death in 1987 was only 9% that in 1957. The largest declines have 
taken place in the older age groups. In absolute terms, this represents 
a decline from an average of 5,027 deaths to 591 deaths per annum, a 
saving of at least 4,436 lives each year.
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11. These estimates make no allowance for the increased number of 
men in these oldest age groups in 1990, which would further increase 
the magnitude of the decline. A better estimate of the number of 
deaths prevented can be obtained by applying age-specific rates from 
the 1950s to 1990 populations. The expected age-specific rates for 
each country were calculated using the earliest five years of data 
available, generally 1950 to 1954, which were applied to the population 
of 1990. The expected number of deaths for each country was then 
compared to the number of deaths observed. In the U.S., 449 deaths 
were observed in 1990. This compares to 14,130 expected deaths had 
the mortality rates of 1950-1954 been applied and means 13,681 
deaths were prevented in that single year. Similar high numbers of 
prevented deaths were found for the Federal Republic of Germany, 
United Kingdom, and Italy.
12. During the period 1957 to 1987, the age-adjusted mortality rate did 
not increase in any country. In Japan, the age-adjusted rate prior to 
1969 was 1.2 per 100,000 per annum, increasing to 1.9 in 1965-69 
before falling to 0.4 per 100,000 in 1985-89. In absolute terms, this 
represents a slight increase from 260 to 269 deaths per annum in this 
time period. In central and eastern Europe, rates have changed slowly 
but remain high, as do mortality rates in South America. However, 
countries in North America, western and northern Europe, and the 
Caucasian populations of Australasia have experienced falls in the 
mortality rate from BPH greater than an order of magnitude over this 
30-year period.
13. Today BPH can no longer be considered as a potentially fatal 
disease and focus has passed on to thinking about symptom alleviation 
and quality-of-life. The invention of the Hopkin's lens and the 
development of the resectoscope has made Trans-Urethral 
Prostatectomy (TURP) a safe and widely used surgical intervention.
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Other invasive treatment modalities exist ranging from open surgery 
through balloon dilatation through a variety of heat and laser 
treatments. In the past 10-15 years there have been major 
developments in a pharmacological approach to the treatment of BPH 
symptoms. Although this has not been without controversy, this has 
become by far the most popular initial choice for truly bothered 
patients either in the form of alpha adrenergic receptor blocking agents 
such as doxazosin, tamsulosin or terazosin, or the 5-alpha reductase 
inhibitors, finasteride and dutasteride.
14. These trends have been confirmed by an up-dated analysis [3] and 
confirm that this decline in mortality is real and reflects a true triumph 
for many aspects of modern medicine notably in that modern 
anaesthesia means that more men can be operated safely and that 
there is better control of infection in the post-op period. Further 
progress in deriving better estimates of the impact of BPH in a 
population will require to come from the development of Symptom 
Scores to allow the disease to be identified in an individual and 
information about a population subsequently derived. Benign Prostatic 
Hyperplasia is no longer a fatal condition.
Z J  Symptom Score Use in D ifferent Populations
15. The majority of progress in understanding the epidemiology of 
benign urological conditions has resulted from the development of 
symptom scores which can estimate the burden of symptoms of a 
condition. The International Prostatic Symptom Score (I-PSS) is the 
accepted international gold-standard for BPH symptoms: this is based 
strongly on the American Uroiogicai Association Symptom Index 
derived by Michael Barry. This gold standard was able to be established 
consequent to the development of a methodology for conducting 
linguistic and cultural translations of the I-PSS into different languages
14
[4]. This methodology has been applied to the I-PSS in several 
countries [5] and has also been employed in the translation of other 
questionnaires [6].
16. The I-PSS was translated into French and then followed a linguistic 
and cultural validation. The resultant questionnaire was then employed 
in a large survey of Urinary Tract Symptoms in a representative sample 
of the French population. The findings from that survey provided the 
first information about BPH and Lower Urinary Tract Symptoms (LUTS) 
in France [7-10].
2.4 Distribution and Prevalence o f LUTS worldwide
17. Using the process established, linguistic and cultural translations of 
the I-PSS emerged in many languages and enabled comparisons to be 
made between the prevalence of symptoms in many countries 
simultaneously, secure that the questions were deriving similar 
information in each community [11-13].
18. The Fifth report of the International Consultation on Benign 
Prostatic Hyperplasia (BPH) noted with considerable satisfaction the 
improvement in the extent and quality of the knowledge base in the 
Epidemiology and Natural History of Benign Prostatic Hyperplasia [14], 
However, with increasingly available data some issues take on a 
different focus. For example, it is clear that there is a very wide range 
of reported prevalence data, even within age groups, from international 
studies of LUTS-BPH prevalence. Before when there were relatively few 
data, this variation was not so obvious: the delight of the Committee 
was having some real data. However, this situation is now beginning to 
be a cause for some concern and there is an overwhelming need to re­
evaluate the published information and to begin the process of setting 
standards for epidemiological studies in this area.
15
19. With the standardisation of the instruments to collect data, it is 
easier to make international comparisons and understand the 
geographical patterns of BPH prevalence. Cultural differences across 
countries may. In fact, still produce a different impact on the lifestyle, 
but the use of culturally and linguistically validated questionnaires 
increased the homogeneity of data. Although hospital-based surveys 
are very interesting to understand and analyse changes in treatment- 
and diagnostic-trends, population health surveys are required to 
estimate the frequency of BPH in the community.
20. Over the five years 1995-1999, studies of urinary symptoms and 
benign prostatic hyperplasia have been undertaken in a number of 
countries. Some of the surveys have involved probability samples of 
entire countries (Canada, France). Some have represented age- 
stratified random or attempted total enrolment of male residents of 
communities meeting certain age and eligibility criteria (Olmsted 
County, Minnesota; a small fishing village in Japan; several 
communities in the Forth Valley Scotland; Madrid, Spain; Porirua, New 
Zealand; Kiryat Hayovel, Israel; North West Thames Health Region, 
England; Copenhagen, Denmark; Rotterdam, Holland; Trondheim, 
Norway). Some have enrolled samples of men from one or more 
general practices (Maastricht, Holland; Leicestershire, England). Some 
have involved hospital clinic populations (Seoul, Korea) or respondents 
to an advertisement for a prostate screening program (Singapore). 
Some have involved a number of different sampling methods in several 
different countries.
21. However, while many of the surveys used linguistically validated 
versions of the I-PSS, some involved self-administration, some used 
mail-administration, some used in-person interviews and some used 
telephone interviews. It is worth noting that scores on the ALIA 
Symptom Index have been shown to be slightly lower when obtained
16
by in-person or telephone interview, as compared to self­
administration.
22. Some investigators have noted difficulties in translating concepts 
from the English version of the IPSS into certain languages. For 
example, Pakistani investigators have noted difficulties in translating 
concepts into Urdu. In some countries it is customary to conduct 
medical examinations of men waiting together in large groups for the 
examination. When questionnaires are completed in such settings it is 
possible that answers could be different from what may be obtained in 
mail-based or home-based administration. In some cultures it is less 
common to discuss one's health problems openly than in others. Even 
in English-speaking populations there seem to be differences in how 
symptoms are perceived and reported in questionnaires. Finally, as 
many authors have observed, lower urinary tract symptoms are highly 
non-specific and can be elevated by factors having nothing to do with 
prostatic conditions. Such factors include diet, fluid intake, alcohol 
intake, and anticholinergic effects of commonly used non-prescription 
medications. For all these reasons it is difficult to draw etiologic 
conclusions from cross-cultural comparisons of symptoms. Nonetheless, 
symptom comparisons are useful in describing the patient-perceived 
problems in this medical area and within-country analyses may help 
refine methods for the study of urological conditions [14].
23. In considering all the available evidence regarding the Epidemiology 
and Natural History of Benign Prostatic Hyperplasia, the Committee of 
the Fifth International Consultation on BPH were able to formulate a 
number of Recommendations as priority for future research directions. 
The background and the rationale for these recommendations is 
explained in the main text of the report [14] These recommendations 
include (1) Community-based distributions o f LUTS, prostate size and 
peak urofiow rates by age on each continent shouid continue to be
17
determined; (2) Community-based occurrence on the concomitance o f 
benign uroiogicai conditions such as LUTS, Male Erectile Dysfunction 
and Urinary Incontinence shouid be established with priority; (3) 
Community-based occurrence on the concomitance o f benign uroiogicai 
conditions and other chronic conditions such as hypertension and 
vascular disease should be established; and (4) The epidemiology o f 
doctor-seeking behaviour in men with LUTS shouid be a m atter o f 
priority.
2.5 The UrEpiK Study
24. While great progress has been made on the epidemiology of Benign 
Prostatic Hyperplasia, the situation with regard to other common, 
benign urological conditions remains very poor. In order to make 
advances, a population-based, multi centre study was undertaken and 
completed in four countries. The Netherlands, France, United Kingdom 
and Korea, to study the epidemiology of these conditions. This study 
was a cross-sectional Survey o f Benign Prostatic Hyperplasia, Urinary 
Incontinence, Prostatitis, Cystitis and Male Erectile Dysfunction in the 
United Kingdom, France, the Netherlands and Korea (The UrEpiK 
Study) [15].
25. The UrEpiK study is a descriptive epidemiological study which 
involved the recruitment of a random sample of men and their 
partners, if they had one. The recruitment was carried out in a defined 
geographical region in one of four international populations. These 
centres were Boxmeer (the Netherlands), Auxerre (France), West 
Midlands (United Kingdom) and Seoul (Korea). The main aim of the 
survey was to obtain population prevalence of Benign Prostatic 
Hyperplasia (Lower Urinary Tract Symptoms), Urinary Incontinence, 
Interstitial Cystitis, Prostatitis and Male Erectile Dysfunction in each of 
the four participating study centres.
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26. Once the man had agreed to participate in the study and had given 
informed consent according to local requirements, a baseline 
questionnaire was administered. A common questionnaire was 
employed in each centre. Standard questionnaires, supplemented with 
extra questions, were employed in this study as far as possible. 
Furthermore, a series of questions were added to investigate the 
knowledge and attitudes of the population groups to these urological 
conditions. In particular, probes were developed to investigate what 
drives individuals to seek medical advice regarding urinary symptoms 
and how their behaviour, including social life, is effected by their 
symptoms.
27. The majority of progress in understanding the epidemiology of 
benign urological conditions has resulted from the development of 
symptom scores which can estimate the burden of symptoms of a 
condition. The International Prostatic Symptom Score (I-PSS) is the 
accepted international gold-standard for BPH symptoms; Oleary and 
colleagues have developed a Sexual Function questionnaire which 
assesses erectile function; questions from the questionnaire of Nickel 
and Sorensen for Prostatitis and the Interstitial Cystitis questionnaire 
of Oleary were also employed. Urinary Incontinence was assessed 
using the Questionnaire of Vierhout. Quality of Life was assessed using 
the SFI 12. These methodological issues were published in more detail 
just as the study was about to start [15].
28. Two levels of data collection were employed in each centre. The 
first level was for the collection of basic data through questionnaires 
and did not require any invasive testing. At the second level a small 
number of tests were performed on a sub sample of the responders to 
the first level. This sub-sample of men had a urological examination 
including a digital rectal examination, trans-abdominal or trans rectal 
ultrasound and urofiow measurements. They also completed the
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urological part of the level 1 questionnaire again. This Level 2 sample 
permits the validation of some of the information collected by the 
questionnaire in Level 1. In particular, the sensitivity and specificity of 
the I-PSS questionnaire, and the sub-scores of irritative and obstructive 
symptoms, to the diagnosis of (true) benign prostatic hyperplasia could 
be investigated.
29. This study employed culturally, and linguistically validated versions 
of standard questionnaires to address the prevalence of the symptoms 
and the impact on quality of life of the men and their partners. The 
samples were selected randomly from population registers of men aged 
40-79. This provided representative samples in each community [15]. 
The first level of data collected used postal questionnaires in the 
European centres and an interviewer in Korea. The second level 
involved a repetition of part of the questionnaire and a urological 
examination to a 10% sub sample of the respondents to the first level.
2.5.1 BPH/LUTS
30. It is important to start with an analysis of Lower Urinary Tract 
Symptoms (LUTS) to give some indication of how well the findings from 
UrEpiK correspond with those of other similar surveys. In addition, the 
epidemiology of lower urinary tract symptoms among men and women 
has significant unanswered questions concerning prevalence and 
impact in different populations [16]. One particular issues relates to the 
impact of such symptoms on quality-of-life.
31. 4969 index men and 3790 women were recruited with response
rates among men of 77% in Boxmeer, 21% in Auxerre, 49% in 
Birmingham and 65% in Seoul. The percentages of men and women 
with scores on the IPSS of 8-35, indicating the presence of moderate to 
severe symptoms were, men first, 20.6, 17.9 (Boxmeer); 17.5, 12.5 
(Auxerre); 26.5, 22.4 (Birmingham); 16.7, 19.9 (Seoul). Among
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women the relationship between symptoms and age is not as steep as 
compared to men. The percentages of men and women with moderate 
to severe symptoms were, men first, 11.8, 15.8 (40-49); 20.3, 17.7 
(50-59); 31.2, 24.3 (60-69); 41.8, 31.3 (70-79). Among 40-49 year 
olds the main differences between men and women come from the 
questions about the frequency of urination during the day and holding 
back urine. Among the older age groups men reported more 
symptoms on all questions apart from urination at night and difficulty in 
holding back urine, both of which were equally prevalent among men 
and women [17].
32. The overall prevalence of LUTS was significant and showed no 
marked cultural variation. Prevalence increases with age with severe 
LUTS commoner in older men. Women report similar levels of the 
symptoms traditionally associated with LUTS in men further 
demonstrating the non-specificity of the IPSS. In each age group the 
frequency of LUTS is similar to men and there are no major cultural 
differences. There are age differences between men and women: 
younger men have a lower prevalence than younger women but older 
men a much higher prevalence than older women. These findings 
emphasise that the IPSS be confined to within-patient comparisons and 
not as a diagnostic tool. The IPSS performs very similarly regardless of 
sex and a more sensitive instrument for use in BPH is required [17].
2.5.2 Lower Urinary Tract Symptoms (LUTS) and Quality of Life
33. It has been hypothesised that as the severity of lower urinary tract 
symptoms (LUTS) increased, the impact as measured by the BPH 
Impact Index (BII) would also increase. The UREPIK survey was 
designed to collect this information from men in four countries: The 
Netherlands, Korea, France and the United Kingdom. The purpose of
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this study was to test this hypothesis and describe to what extent the 
impact can be explained by LUTS.
34. This Is the first study to employ culturally, and linguistically 
validated versions of standard questionnaires, the BPH Impact Index 
(BII), the SF-12 and the International Prostate Symptom Score (IPSS), 
to address the distribution of symptoms and the Impact on quality of 
life of LUTS in men and their partners. A random selection mechanism 
with the aim of providing representative samples of the male 
population aged 40-79 in each community was used for recruitment. 
Regression analyses were undertaken on SF-12, the total BII and IPSS 
scores.
35. A total of 4800 index men and 3674 women responded to all the 
questions discussed, BII increased with increasing IPSS score. The 
correlation coefficients were: Boxmeer 0.65, Auxerre 0.66, Birmingham 
0.60, and Seoul 0.66. Among men with an IPSS score of 0-7, the mean 
(standard deviation) BII score was 0.25 (0.90), 1.8 (2.2) for IPSS 8-19 
and 4.5 (2.3) for IPSS 20-35. For women, the correlations were 
slightly lower except in Birmingham: 0.59 (Boxmeer), 0.48 (Auxerre), 
0.71 (Birmingham), 0.57 (Korea). The impact of the symptoms is 
higher in women than in men with the same level of symptom severity. 
The mean (SD) BII among women with an IPSS score of 0-7, was 0.48 
(1.30), 1.6 (2.7) for IPSS 8-19 and 5.4 (3.4) for IPSS 20-35. Adjusting 
for symptom severity there is no association between age and bother. 
Younger men and women with severe to moderate symptoms do not 
experience more bother with this level of symptoms than older men 
and women.
36. There was an association between the score on the quality of life 
question in the IPSS (question 8 in the IPSS) and BII. For men the 
correlation was 0.63 and for women it was 0.60. The BII scores range
22
from 0-13 and among men who are delighted or pleased with their 
urinary condition (scores 1 and 2 on IPSS question 8) the mean (SD) 
BII score is 0.1 (0.6), for those who are mostly pleased or mixed the 
score is 1.0 (1.4) while for those who are dissatisfied /unhappy/ terrible 
the score is 4.5 (2.6). Among their partners the scores are 0.3 (0.9),
1.5 (2.1), 4.5 (3.3), respectively. Men and women with the same level 
of satisfaction (IPSS question 8) report the same bother. Among those 
with an IPSS score of 20-35 women express significantly more bother 
(p<0.001). The SF-12 scores decreased as the IPSS and the BII 
Increased in men and women. Furthermore, the SDF-12 mental score 
decreased with increasing symptom scores in the partner [18].
37. The pattern of the relationship between severity of LUTS and BII is 
very similar between three European centres and the Far Eastern 
centre. More evidence is needed to better explain the relationship 
between symptoms and disease impact in men with LUTS although 
there is a clear association between the BII and the IPSS Quality of Life 
question in men and women. The BII discriminates between people 
who are unhappy about their urinary condition compared to those who 
are not. Greater attention should be paid to the use of this index in 
studying the impact of urinary conditions since it appears to be disease 
specific. Although designed for use in BPH the index also appears to 
be a useful measure of bother among women. The severity of 
symptoms of LUTS has an adverse effect on the individual and his/her 
partner [17].
2.5.3 Urinary Incontinence
38. There is little information on the prevalence and quality of life 
associated with male urinary incontinence (UI). A population-based, 
multicentre study has been completed in four countries. The 
Netherlands, France, United Kingdom and Korea, to study the
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epidemiology of this condition. This study employs culturally, and 
linguistically validated versions of standard questionnaires to address 
the prevalence of the symptoms and the impact on quality of life of the 
men and their partners. The samples were selected randomly from 
population registers of men aged 40-79. This provided representative 
samples in each community.
39. A total of 4969 men and 3790 women responded to these 
questions. As measured by an incontinence symptom score 11.1% of 
men aged 40-79 reported mild to severe Incontinence. There were no 
differences over the four centres. Typically the reported incontinence 
was leaking drops of urine a few times a week. Only in 1.7% of men 
was there severe and frequent incontinence. By comparison, on a self 
reported question, 14.3% of men in the UK and Netherlands thought 
that they had urinary leakage, compared to 7.1% of men in France and 
Korea. Of men with urinary leakage in the three European centres, 
24.3% visited the doctor with this problem, compared to only 9.1% of 
Korean men. Very few men received treatment for urinary leakage and 
less than 1% were taking medication. 7.6% of men in the European 
centres used protective pads at least occasionally compared to only 2% 
on men in Korea. Incontinence is age related and the reporting of it is 
also culturally related. 14.7% of men in UK and 13.6% of men in the 
Netheriands aged 40-49 report some symptoms compared to 5% of 
men in France and 2% of men in Korea. Among men aged 60-69 the 
corresponding percentages are 15.6% in the UK, 23.4% in the 
Netherlands, 10.1% in France and 8.5% in Korea [19].
40. It is clear that urinary incontinence is commoner in older men and is 
relatively uncommon among younger men. Some men reported no 
problems on the symptom questionnaire but replied positively to a 
direct question. A surprisingly high number of men wear protective 
pads at least occasionally as a result of their incontinence. Urinary
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incontinence appears to be a reasonably sized problem in men which 
remains largely untreated [19].
2.5.4 Association between LUTS and Erectile Dysfunction (ED)
41. Recent small-scale epidemiological studies have suggested an 
association between benign prostatic hyperplasia (BPH) and sexual 
dysfunction. Both conditions are strongly associated with age and no 
study has been able to exclude age as a confounding factor to this 
relationship. We reported a large-scale multi-national Investigation of 
lower urinary tract symptoms (LUTS) and sexual function that was 
designed to investigate the independent association between these 
conditions. The findings have considerable implications for the 
management of the BPH patient.
42. Culturally, and linguistically validated versions of standard 
questionnaires were used to estimate the prevalence of LUTS (using 
the IPSS) and Erectile Dysfunction (using O'Leary's Sexual Function 
Inventory (SFI)) in regions of the United Kingdom (Birmingham), the 
Netherlands (Boxmeer), France (Auxerre) and Korea (Seoul). In each 
centre, stratified random samples were selected from population 
registers to provide representative samples of the population of men 
aged 40-79 in each community. Face to face interviews were held in 
Seoui and postai questionnaires in the three European centres. The 
samples were selected randomly from population registers of men aged 
40-79, providing representative samples in each community.
43. A total of 4800 men and 3674 women responded to these 
questions. The response rates among men were 77% in Boxmeer, 21% 
in Auxerre, 42% in Birmingham and 65% in Seoul. The overall 
prevalence of erectile dysfunction, for men aged 40 to 79, estimated 
from an ED score of 0 to 4, was 21.1%. There was evidence of a linear
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increase with age (p<0.001) and the pattern was very similar in the 
four centres. From the weighted logistic model, there was evidence of 
an association between sexual dysfunction, other self-reported diseases 
and lifestyle. On the basis of the ED score, after adjusting for age and 
country, men with diabetes were more likely to get a score of 0-4 
(OR=1.57, 95%CI=[1.09; 2.25]), so were those with High Biood 
Pressure (OR=1.38, 95%CI=[1.09; 1.75]) and with an IPSS score of 8- 
35 (OR=1.39, 95%CI=[1.10; 1.74]). For lifestyle, smokers were more 
likely to get a score of 0-4 (OR=l,54, 95%CI=[1.23; 1.92]), while 
physical activity during leisure time was slightly associated with a 
reduction in the odds of having a score of 0-4 (OR=0.87, 
95%CI=[0.77; 0.99]. The analysis was repeated using self-reported ED 
instead of the dichotomised score and the same results were obtained 
[20].
44. Erectile dysfunction is clearly age related and a problem for a large 
proportion of men in the community. It can have a profound impact on 
the quality of life of the man and on his partner. Were all men with 
this problem to seek medical help there would be a large burden on the 
health care systems. There are cultural and age effects on the 
assessment of this problem [20].
45. To help confirm this finding, a large-scaie, community-based, multi­
national investigation of lower urinary tract symptoms (LUTS) and 
sexual function, designed specifically to investigate the independent 
association between these conditions, has been analysed and is 
reported [21]. The findings have considerable implications for the 
management of the BPH patient.
46. Detailed questionnaires were sent by mail to men aged 50-80 years 
in 7 countries (France, Germany, Italy, Netherlands, Spain, United 
Kingdom and USA). The sample in each country was representative of
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the target population In terms of age and social characteristics. LUTS 
and sexual function were assessed by validated symptoms scales 
including the International Prostate Symptom Score (IPSS), the Danish 
Prostate Symptom Score (Dan-PSS), and the International Index of 
Erectile Function (IIEF). Subjects also completed a Health and 
Demographic Questionnaire, including presence of co-morbid medical 
conditions, medication use, smoking and alcohol consumption.
47. 12,815 questionnaires (a response rate of 36.7%) were evaluable 
and included in the analysis. 90% of men had LUTS (6% as severe, 
25% as moderate, and 59% as mild) and only 11% were treated 
medically. Sexual activity was reported by 83% of the sample, with 
71% reporting at least one episode of sexual intercourse in the 
previous 4 weeks. Frequency of sexual activity decreased with age, but 
was strongly associated with the presence and severity of LUTS. 
Erectile function and sexual activity were both independently 
associated with the presence of LUTS, independent of age and 
significant co-morbidities (diabetes, hypertension, hyperlipidaemia, 
heart disease and tobacco consumption). There was also a striking 
(independent) association between abnormal ejaculation and its 
bothersomeness with severity of LUTS. Men reporting mild LUTS 
(IPSS<8) had an odds ratio of 0.26 (95% confidence interval (0.21, 
0.33)) compared to men reporting severe LUTS. The results were 
consistent from one country to another and there was every indication 
that this association was a general male problem and not one limited to 
a selected number of different cultures.
48. In this large-scale, multi-national study of LUTS and sexual 
function, as anticipated, a high prevalence of both LUTS and sexual 
problems was observed particularly in older men. These ejaculatory 
and erectile dysfunctions were strongly related to the severity of LUTS 
and were independent of age and other co-morbidities. There are two
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conclusions from this study that have great clinical significance. Firstly, 
there is a need to investigate the joint aetiology of LUTS and sexual 
problems, especially ejaculation abnormalities [21]. Secondly, it is 
important that ciinicians pay more attention to baseline sexual function 
and/or dysfunction in the initial evaluation, the choice of treatment and 
follow-up of men with LUTS.
2.5.5 Urinary diseases in households
49. In the UrEpiK study, obtaining information on the symptoms of 
several different benign urologicai conditions allows for the first time 
estimates to be obtained regarding the overall burden of such 
conditions on the general population.
50. A total of 4800 men and 3674 women responded, providing 
information on 3474 couples. Among men aged 40-79, 20.3% report 
moderate to severe symptoms of LUTS, 10.2% report some urinary 
leakage and 21.1% report severe problems with ED. In their partners,: 
18.6% report moderate to severe symptoms of LUTS, 33.6% report 
some urinary leakage and 20.0% report some problems with Cystitis.
51. The percentage of men with no urinary problems decrease with 
age. 80% of men aged 40-49 report no problems compared to 20% of 
men aged 70-79. The decrease in women with age is much less: 60% 
of women partners aged <49 report no problems compared to 45% of 
women aged 70-79.
52. The prevalence of these symptoms increase with age. Among 
households where the man is 40-49, 51.9% report no symptoms, while 
both partners report at least one symptom in in 10.6% of households. 
Among households where the man is 60-69 only 25.4% do not have 
any problems and in 27.7% both partners have at least one problem.
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Among households where the man is 70-79, only 12.5% do not have 
any problems and in 38.5% both partners have at least one problem 
[16].
53. The UrEpiK study has clearly demonstrated the magnitude of the 
problem and the impact of benign urological diseases in the general 
population. The burden of benign urological diseases on couples is 
clearly demonstrated. Where the man is aged 70-79, seven out of 
eight couples report the symptoms of at least one benign urological 
condition [16]. As it is well accepted that these diseases interfere with 
the quality of life of the couple, the impact may be considerable.
3 Benign Prostatic Hyperplasia Treatments
3.1 Meta-Analysis o f BPH Treatments
54. There is little doubt that true Benign Prostatic Hyperplasia (BPH) in 
men is androgen dependent. Dihydrotestosterone (DHT) is the active 
metabolite of Testosterone (T) which is responsible for prostate 
growth: 5a-reductase is the enzyme which converts testosterone to the 
active dihydrotestosterone. Furthermore, stromal 5a-reductase activity 
is elevated in the hyperplastic human prostate. For reasons such as 
these finasteride was developed and introduced in the treatment of 
symptomatic benign prostatic hyperplasia in men.
55. In clinical studies, finasteride has been shown to reduce the volume 
of the prostate and to reduce the urinary symptoms in men labeled 
with this condition. The safety and efficacy profile of finasteride has 
been demonstrated in men with symptomatic BPH in one six-month, 
two twelve-month and one 24 month double-blind, placebo controlled 
trials. In all four studies finasteride produced significant improvements
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in symptoms, maximum urinary flow rate and prostate volume 
compared to the placebo treated patients.
56. Finasteride is a 4-azosteroidal inhibitor of human 5a-reductase. 
Inhibition of 5a-reductase results in a decrease in plasma and prostatic 
dihydrotestosterone (DHT) levels. Men with an inherited deficiency in 
the 5a-reductase enzyme provide a human model for studying the 
effects of inhibiting this enzyme. Men with the disorder are born with 
ambiguous genitalia: otherwise their early growth and development are 
normal. Of particular interest was the observation that although these 
subjects virilize substantially at puberty, they have scant facial hair, no 
temporal hair loss, no acne and an undeveloped prostate gland. 
Women with the 5a-reductase deficiency are completely normal which 
suggested that this enzyme is necessary only for the normal 
development of the male external genitalia and primary and secondary 
sexual characteristics and does not have any more general biologic 
function.
57. Testosterone (T) is secreted by the testes and adrenal glands and is 
metabolized peripherally primarily in the liver, skin and prostate by the 
enzyme 5a-reductase to the potent androgen DHT. Finasteride has 
been demonstrated in vitro to be a pure 5a-reductase inhibitor which 
does not compete with DHT for the androgen receptor. DHT is strongly 
bound to the androgen receptor. In rat and human prostatic tissue, 
inhibition of 5a-reductase by finasteride was demonstrated while 
binding of DHT to the androgen receptor is not affected. Studies in the 
rat treated with finasteride demonstrated no progestational, 
gonadotropin inhibitory, androgenic estrogenic or anti-estrogenic 
effects. In intact rats and dogs, the only important effect produced by 
finasteride was a reduction in prostate size.
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58. Not all men respond to finasteride and there are apparent 
discrepancies in the responses found in the available randomised trials 
involving finasteride use. It was not clear whether any baseline 
characteristics of the disease in individual men could indicate the 
outcome of finasteride therapy. With data available from six, placebo- 
controlled clinical trials involving two thousand six hundred men with 
BPH treated with finasteride (at 5 mg for one year) or placebo it 
seemed appropriate to examine whether there are any variables which 
could predict the outcome of finasteride treatment and to indicate 
which men should be candidates for finasteride therapy and which men 
are unlikely to respond to finasteride and who may be better suited to 
another therapeutic approach from the outset.
3.1.1 Meta-Analysis of Finasteride
59. Six randomized clinical trials were available comparing one year of 
5mg finasteride and placebo for treating clinical benign prostatic 
hyperplasia (BPH). Findings had been published from four studies and 
data from the remaining two incomplete and unpublished studies were 
given to the author thereby avoiding the potential phenomenon of 
publication bias. The findings for the 2601 men in these trials provide 
an opportunity to investigate the heterogeneity of the effects seen in 
the individual studies and to identify pre-treatment predictors of 
outcome as expressed by prostate volume, symptoms, or peak urinary 
flow rates. Identifying these predictors is important and meta-analysis 
is useful because of the increased range of baseline values: for 
example, the mean prostate volume ranged from 32 cc to 60 cc in the 
six studies.
60. A formal meta-analysis using an Empirical Bayes approach, 
employed data from all finasteride Phase III trials in North America and 
Internationally, the Canadian, Early Intervention, and SCARP trials, and
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the VA cooperative study comparing terazosin and finasteride in 
combination. A pooled analysis was also undertaken on the combined 
dataset. The statistical analysis is based on Empirical Bayes principles 
Full details are included in the publication [22].
61. There were consistent effects across all six trials for finasteride and 
improvements in peak urinary flow rate, prostate volume and total 
symptom score among men with similar prostate volumes at baseline. 
Flow rate and symptom score change differed little between finasteride 
and placebo among men without enlarged prostates at baseline: 
symptom and flow rate improvement became more pronounced with 
increasing initial prostate volume. Baseline prostate volume is a key 
predictor of treatment outcome: approximately eighty per cent of the 
variation in the treatment effect could be attributed to differences in 
mean prostate volume between studies. Variations in entry criteria, 
associated with the lack of any uniform definition of BPH, resulted in 
large differences in baseline prostate volume and, consequently, 
apparent inconsistencies in the overall outcome of the trials [22].
62. It can be concluded based on this analysis [22], that there is a 
material effect of one year of finasteride therapy on reducing prostate 
size, on increasing maximum urinary flow rate, on reducing total 
symptom score and on reducing the quasi-AUA symptom index which is 
consistent across the six randomized trials. Men who received 
finasteride for one year in these trials had smaller prostates after one 
year's treatment than controls, had increased flow rates compared to 
controls and had lower symptom scores than controls. Not much 
difference in maximum urinary flow rate change between finasteride 
and placebo can be expected in men without enlarged prostates but 
that improvement in maximum urinary flow rate on finasteride 
becomes more pronounced with increasing prostate volume. A similar
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situation was found with other treatment outcome measures such as 
total symptom score and quasi-AUA index [22].
63. Much of the apparent discrepancies observed between the outcome 
in the different trials can be ascribed to the role of chance given the 
major differences in the distribution of prostate volume between the 
trials conducted [22]. It seems reasonable on physiological grounds 
that larger prostates respond in a stronger manner to finasteride 
therapy than do the smaller prostates since these are the glands which 
are most likely to have true histological hyperplasia. In all these trials 
the diagnosis of BPH is made on clinical grounds and there have been 
no biological specimens removed for confirmatory histological 
confirmation.
64. In the light of these findings it appears to be important and timely 
to reconsider the terminology employed in the study of Benign Prostate 
Hyperplasia in order to seek better definitions of specific diseases and 
conditions. The overall umbrella condition is Lower Urinary Tract 
Dysfunction (LUTD) which leads through some or other mechanism to 
the development of a wide range of urinary symptoms, detrusor 
dysfunction, incomplete emptying of the bladder, pressure flow 
disturbances, urinary tract infections, urinary obstruction, urinary 
retention and haematuria. It is increasingly evident that true Benign 
Prostatic Hyperplasia is only one of the conditions included in this 
overall category and that a better, and more precise, definition of this 
condition, paying attention to the importance of prostate enlargement, 
could provide a clearer basis for Indications for therapy for men with 
urinary problems.
65. This meta-analysis and pooled analysis of all available randomised 
trials of finasteride has subsequently changed treatment practices 
world-wide (the manufacturers (Merck) changed their label to exclude
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small prostates) and has led to revisions in the terminology used to 
classify lower urinary tract symptoms in men. It has become one of the 
most cited publications in Benign Prostatic Hyperplasia [22].
3.1.2 Relationship between prostate volume and serum prostate specific 
antigen (PSA) in men without evidence for prostate cancer
66. Having demonstrated that prostate volume is a necessary indicator 
when choosing the correct treatment for a man with lower urinary tract 
symptoms (LUTS), practical considerations need to be addressed. From 
the trials available, the prostate volume had been measured by MRI 
which is expensive, time consuming and may lead to lack of patient 
compliance. The alternative, the transrectal ultrasound, is quite 
unpleasant to a lot of men and the results can be sometimes 
misleading (depending on the shape and orientation of the prostate). 
An accurate, acceptable and simple method to estimate prostate 
volume would be a great advantage.
67. It is well established that prostate size increases with advancing 
age. Cross-sectional data are available from autopsy studies, 
population based studies and clinical studies in men with benign 
prostatic hyperplasia (BPH) to demonstrate this relationship. In 
addition, longitudinal studies of prostate growth in population based 
studies have demonstrated a yearly growth of 0.7 to 1.5 ml/year over 
four years.
68. A relationship between age and serum prostate specific antigen 
(PSA) has also been established. This relationship forms the scientific 
basis for the development of the age specific reference ranges for 
serum PSA recommended in screening men for prostate cancer. In a 
detailed analysis of the baseline information on men with no evidence 
for prostate cancer by DRE enrolled into either studies of BPH (age 40
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and above) or alopecia (age 20-60) a strong log-log iinear relationship 
between serum PSA and prostate volume was identified [23]. This 
reiationship allows physician to estimate with sufficient accuracy 
prostate volume without having to resort to TRUS measurement prior 
to initiating therapies for BPH for which the ultimate outcome is 
dependent on baseline prostate volume as is the case for finasteride.
3.1.3 Serum prostate-specific antigen and long-term changes in symptoms 
and flow rate
69. Having demonstrated a relationship between prostate volume and 
response to therapy in men with BPH [22] and between prostate 
volume and serum levels of Prostate Specific Antigen (PSA) [23], it 
became obvious to investigate the association between serum PSA and 
response to treatment. This was done in the four-year PLESS trial [24] 
and the aim was to determine whether baseline prostate-specific 
antigen (PSA), in addition to prostate volume, is associated with long­
term changes in symptoms and urinary flow rate.
70. Three thousand and forty men with benign prostatic hyperpiasia 
enrolled in the PLESS trial were randomly assigned to finasteride 5 mg 
or placebo for 4 years. Symptoms and flow rate were assessed every 4 
months, and data were analyzed by dividing the patients into three 
groups by baseline PSA tertiles (0 to 1.3, 1.4 to 3.2, and 3.3 ng/mL or 
greater) and baseline prostate volume tertiles (14 to 41, 42 to 57, and 
58 to 1 50 mL).
71. After the initial placebo effect, a slow deterioration in symptoms 
over time was observed in the placebo-treated men with a baseline 
PSA 1.4 ng/mL or greater. However, placebo-treated men in the lowest 
PSA tertile (less than 1.4 ng/mL) had sustained symptomatic 
improvement that was not seen in placebo-treated men in the higher 
tertiles (P<0.001). In all finasteride-treated groups, there was initial
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improvement followed by maintenance or continued symptom 
improvement over time (approximately 3 to 3.5 points by the end of 4 
years). The differences in symptom score improvement between 
placebo and finasteride were marginal for men with baseline PSA levels 
less than 1.4 ng/mL (P = 0.128) but were highly significant for men 
with PSA levels 1.4 ng/mL or greater (P<0.001). Urinary flow rate 
results were similar to those observed for symptoms. Analysis of 
symptom and flow rate data by prostate volume tertiles in a 10% 
subset of men yielded similar results, namely a deterioration of 
symptoms and flow rate in the two higher tertiles treated with placebo 
(greater than 41 mL) and a sustained improvement in all three groups 
of finasteride-treated patients.
72. Baseline PSA and prostate volume are good predictors of long-term 
symptomatic and flow rate changes. Baseline PSA levels of 1.4 ng/mL 
or greater and enlarged prostate glands predict the best long-term 
response to finasteride compared with placebo [24]. The use of PSA in 
determining men with LUTS suitable for finasteride therapy is apparent.
3.1.4 Acute Urinary Retention
73. Acute urinary retention is an unpleasant, painful experience which 
requires immediate medical, and frequently surgical intervention. 
Population studies reveal that acute urinary retention is a common 
event: a 60 year-old man who survives a further 20 years has a 23 per 
cent probability of experiencing an acute episode of urinary retention. 
About half of acute retention episodes appear to be linked to general 
anaesthesia and a further large proportion due to the natural history of 
benign prostatic hyperplasia.
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3.1.5 Acute Urinary Retention -Epidemiology
74. The risk of acute urinary retention increases with increasing age. 
There are a number of other risk factors with risk increased in men 
with moderate and severe urinary symptoms, low peak urinary flow 
rates (less than 12 ml/sec) and among men with large prostates [25]. 
When simultaneous correction was made using logistic regression, 
baseline age, AUA Symptom Index. (I-PSS), initial peak flow rate and 
were independent predictors of outcome. Prostate volume could not be 
entered into the model due to the small numbers of subjects, but in an 
unadjusted analysis, the relative risk of acute urinary retention among 
men with prostates greater than 30 ml (on ultrasound) was 3.0 
compared to the referent group (less than 30 ml). This probably covers 
all enlarged prostates as determined by the digital rectal examination, 
and over half of all patients being treated from BPH [25].
75. Thus, given that finasteride has a positive effect on three of the 
four risk factors for acute urinary retention (reduces symptoms, 
increases flow rate, reduces prostate volume) it could be expected that 
long-term finasteride use would lead to a reduction in AUR.
3.1.5.1 Long-term Outcomes of Finasteride therapy in men with BPH
76. Reduction of urinary symptoms and improvement in urinary flow 
rate are the immediate short-term goals of therapy for benign prostatic 
hyperplasia. However, it is widely accepted that BPH is a progressive 
disease and it has frequently been of interest as to whether treatment 
for symptoms could lead to a reduction in prostate surgery and acute 
urinary retention, the more serious end-points of BPH.
77. Occurrences of acute urinary retention were investigated in a 
pooled analysis of three placebo-controlled, randomised clinical trials of
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two years of finasteride therapy (5 mg daily) in men with benign 
prostatic hyperplasia [26]. These men had been recruited to three 
different randomised trials which utilized an identical protocol (further 
details in [26]). These studies involved a total of 4,222 men with 
moderately symptomatic BPH: a total of 2,113 men received finasteride 
and 2109 placebo.
78. In the primary analysis, occurrence of AUR were analysed by the 
Kaplan-Meir method and the hazard ratio, and corresponding 95% 
confidence intervals calculated. The primary analysis was intention-to- 
treat. A total of 57 men (out of 2109) on the placebo experienced on 
acute urinary retention (2.7 per cent). This compares to 24 (out of 
2113) on finasteride (1.19%) and the corresponding hazard ratio was 
0.43 (0.28, 0.67) [26].
79. Identical findings have emerged from two other sources. In a four- 
year randomised trial (PLESS), 3016 men were included (1513 on 
finasteride and 1503 on placebo). A blinded Data Monitoring Committee 
evaluated all cases of acute urinary retention reported. 98 men in the 
placebo group (6.5%), compared to 42 men (2.8%) on finasteride, 
experienced on acute urinary retention. The hazard ratio was 0.43 
which is identical to that found in [24]. Similarly, the recently 
completed Phase III studies of dutasteride (another five alpha 
reductase inhibitor) demonstrated the exact same hazard ratio in a 
two-year study.
80. The proportion of the placebo group going into acute urinary is 
substantial and there is good agreement in a 57 per cent reduction in 
the risk of acute urinary retention associated with use of five-alpha 
reductase Inhibitors {finasteride dutasteride).
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3.1.5.2 Comparison of 5ARIs and Aipha-blockers in Prevention of AUR
81. It has been clearly demonstrated (above) that five-alpha reductase 
inhibitors can reduce the risk of Acute Urinary Retention (AUR). 
Although an effect of alpha-blockers on the risk of acute urinary 
retention has been proposed. It has not been so ciearly demonstrated. 
This analysis examines the relative effectiveness of current medical 
therapies for BPH in preventing AUR, AUR-reiated catheterisation and 
surgery in real-life clinical practice, using a large prescription database 
[27].
82. This is a retrospective analysis of observational data from the 
General Practice Research Database (UK) (GPRD). The cohort contains 
4500 patients experiencing BPH or lower urinary tract symptoms 
strongly suggestive of BPH, aged over 50 years, who were prescribed a 
5ARI (finasteride) or an alpha-blocker (alfuzosin, doxazosin, indoramin, 
prazosin, tamsuiosin, terazosin) as their first BPH treatment between 
1996 and 1999 inclusive. Cox regression and competing risks analyses, 
adjusted for age and year of first treatment, followed patients from the 
start of their first BPH treatment to AUR, catheterisation or surgery, or 
censoring [27].
83. Patients prescribed an alpha-blocker were significantly more likely 
to experience AUR (hazard ratio 2.32, 95%CI 1.37, 3.94) or surgery 
(hazard ratio 1.78, 95%CI 1.30, 2.44) than patients prescribed a 5-ARI. 
These differences were sustained with sensitivity analyses.
84. Real-life clinical practice shows that significantly fewer BPH patients 
prescribed a 5ARI experienced Acute Urinary Retention and other 
serious complications associated with the progression of BPH compared 
with those prescribed an alpha-blocker [27].
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3.1.6 Designing Trials of a new 5ARI (Dutasteride)
85. In the light of the relationship between outcome of treatment with 
finasteride, the association of PSA with response and the reduction in 
Acute Urinary Retention after two years, the randomised PHASE III trial 
of a new five-alpha reductase inhibitor dutasteride was designed from 
the methodological viewpoint by myself.
86. To study the efficacy and safety of dutasteride, a novel, potent dual 
inhibitor of the 5 alpha reductase (5AR) isoenzymes type 1 and 2, in 
men with lower urinary tract symptoms (LUTS), prostatic enlargement 
and likely bladder outlet obstruction due to benign prostatic hyperplasia 
(BPH). A total of 4325 men with clinical BPH, moderate to severe 
symptoms, a peak flow rate of <15 ml/sec, a TRUS-measured prostate 
volume of >30 cc and a serum PSA 1.5-10.0 ng/mL (inclusive) were 
enrolled into three identical clinical trials and randomized to 0.5 mg 
dutasteride daily or placebo. After a 1-month, single-blind, placebo 
lead-in, patients were followed for 24 months with multiple interval 
assessments.
87. At 24 months, serum DHT was reduced from baseline by 90.2% and 
total prostate / transition zone volume was reduced by a mean of 25.7 
and 20.4% respectively. AUA-SI was improved as early as 3 months 
with pooled significance from 6 months onwards and a reduction of 4.5 
points at Month 24. Maximum flow rate improved significantly from 1 
month, with an increase of 2.2 mL/sec reported at Month 24. Risk 
reduction of acute urinary retention was 57% and risk reduction of 
BPH-related surgical intervention was 48% compared with placebo. The 
drug was generally well tolerated [28].
88. Dutasteride, a potent inhibitor of DHT, is safe and effective in terms 
of reduction of prostate volume, symptoms, flow rate improvement and
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the risk of AUR and surgery. The results fit directly onto the regression 
line established by the finasteride meta-analysis [22].
89. Detailed examination of the impact of dutasteride treatment on 
quality of life was undertaken within this clinical trial. The effect of 
dutasteride on benign prostatic hyperplasia (BPH)-specific health 
status, as measured by the BPH Impact Index (BII), and the 
identification of baseline and treatment risk factors for those most 
bothered by their BPH symptoms at the end of the protocol, was 
undertaken [29].
90. Data were derived from three randomized, double-blind, placebo- 
controlled, 2-year studies conducted in 4325 men with lower urinary 
tract symptoms caused by benign prostatic enlargement. Each study 
comprised a 1-month single-blind placebo run-in period, followed by 
randomization to oral dutasteride 0.5 mg once daily or placebo for 2 
years. Patients eligible for inclusion were consenting men aged >/= 50 
years with moderate to severe symptoms (American Urological 
Symptom Index, AUA-SI, score >/= 12), a prostate volume of >/= 30 
mL, a serum prostate-specific antigen (PSA) level of >/= 1.5 or < 10 
ng/mL, and a maximum urinary flow rate (Qmax) of </= 15 mL/s [29].
91. BII scores were recorded at baseline and each study visit. Clinically 
and statistically significant changes in BII scores from baseline were 
investigated for each study visit. Logistical regression analysis was used 
to assess the significance of baseline prostate volume, symptoms, BII 
item 3, baseline Qmax, serum dihydrotestosterone, testosterone, PSA, 
age and weight in predicting the BII score at two years.
92. Dutasteride, but not placebo, resulted in clinically and statistically 
significant improvements in mean BII score from 6 months. Of patients 
with a baseline BII score of >/= 5 (greatest symptomatic burden)
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treatment with dutasteride improved the scores by 2.41, while the 
scores in placebo-treated patients only improved by 1.64. Dutasteride- 
treated patients with a baseline BII score of < 5 (least symptom 
burden) had a clinically significant improvement in health status, while 
placebo-treated patients deteriorated. Regression analysis showed that 
men with a combination of a baseline BII item-3 score of 3 (bothered a 
lot) and a high symptom score (AUA-SI > / -  20) were more likely to be 
bothered by their symptoms at the end of the study. Men receiving 
placebo were also more likely to be bothered at the end of the study 
than were those receiving dutasteride [29].
93. Dutasteride treatment is associated with clinically significant 
improvements in BII score, reflecting improvements in the quality of 
life of men with BPH. Taken together with previously reported 
improvements in prostate volume, lower urinary tract symptoms and 
urinary flow, and diminution of the risk of acute urinary retention and 
the need for BPH-related surgery, dutasteride offers demonstrable 
efficacy in the management of BPH.
3.1.7 Comparison of 5ARIs and Alpha-blockers in treatment of LUTS
94. With both alpha-blockers and five-alpha reductase inhibitors 
demonstrating efficacy in reducing lower urinary tract symptoms it was 
a logical development to evaluate the joint efficacy of agents from both 
drug classes in symptomatic men. I was a member of the Working 
Group which designed a study to evaluate the efficacy and tolerability 
of the selective alpha(l)-adrenergic antagonist doxazosin and the 5- 
alpha-reductase inhibitor finasteride, alone and in combination, for the 
symptomatic treatment of benign prostatic hyperplasia [30].
95. In a prospective, double-blind, placebo-controlled trial, 1095 men 
aged 50 to 80 years were randomized to treatment for 52 weeks with
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doxazosin, finasteride, the combination of doxazosin and finasteride, or 
placebo. The dose of finasteride (or its matched placebo) was 5 
mg/day. Doxazosin (or its matched placebo) was initiated at 1 mg/day, 
and titrated up to a maximum of 8 mg/day over approximately 10 
weeks according to the response of the maximal urinary flow rate 
(Qmax) and International Prostate Symptom Score (IPSS). The IPSS 
and Qmax were assessed at baseline and at weeks 10, 14, 26, 39, and 
52 or at the endpoint.
96. An intent-to-treat analysis of 1007 men showed doxazosin and 
doxazosin plus finasteride combination therapy produced statistically 
significant improvements in total IPSS and Qmax compared with 
placebo and finasteride alone (P <0.05). Finasteride alone was not 
significantly different statistically from placebo with respect to total 
IPSS and Qmax. All treatments were generally well tolerated [30].
97. Doxazosin was effective in improving urinary symptoms and urinary 
flow rate in men with benign prostatic hyperplasia, and was more 
effective than finasteride alone or placebo. The addition of finasteride 
did not provide further benefit to that achieved with doxazosin alone.
3.1.8 Predictive Model for Acute Urinary Retention
98. The (very) similar nature of the findings of protection of Acute 
Urinary Retention in the three main randomised trial (described earlier) 
indicate the potential importance of being able to identify men at an 
elevated risk of developing Acute Urlnaty Retention.
99. Benign Prostatic Hyperplasia (BPH) is a progressive condition that is 
characterised by an increased risk of acute urinary retention (AUR) and 
BPH-related surgery. AUR presents a high-risk in older men although
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there has been no attempt to predict individual men at high risk of this 
condition.
100. Three 2-year multi-centre, double-blind, placebo-controlled studies 
were conducted (n = 4325); dutasteride was administered at a dose of 
0.5 mg/day. AUR was defined as inability to urinate requiring catheter. 
The three independent studies were designed for a pooled analysis and 
this report is restricted to the placebo control group(s).
101. There were 90 episodes of AUR determined among the 2,158 men 
in the control group in this study: the crude incidence of AUR was 
4.2%. The risk of AUR was independently associated with Qmax, 
Prostate Volume and baseline PSA. Compared to the highest Qmax (13- 
33 ml/sec)(Hazard Ratio (HR)=1), the risk of AUR in the group with the 
lowest Qmax (<7 ml/s) was 4.5 (p for trend p<0.0006). For prostate 
volume, the risk in the group with the largest volume (69cc or more) 
was 6.3 (95% Cl (5.9,23))(P trend (p<0.0001). For PSA, the risk in the 
five categories was 1 (PSA <2), 1.2 (2.1-2.9), 2.5 (2.9,4), 3.9 (4.1, 5.8) 
and 6.3 (PSA of greater than 5.9)(P trend (p<0001). After adjustment 
there was no association between risk of AUR and AUASI or age. A 
multidimensional model has been developed to predict individual risk 
and validated in the treatment group with good results [31].
102. AUR is an important hazard for ageing men and one which can 
profoundly affect quality of life. Risk factors for AUR have been 
identified and a multidimensional model has been developed. 
Identifying men at high risk of AUR should increase prospects for 
prevention since it has been convincingly demonstrated that 
pharmaceutical intervention can significantly reduce the risk of AUR.
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3.1.9 Impact of Treatment of Lower Urinary Tract Symptoms /  Benign 
Prostatic Hyperplasia
103. The most recent published guidelines on the Treatment of Lower 
Urinary Tract Symptoms/Benign Prostatic Hyperplasia are based on 
many of the findings which emerged from the work described above. 
Prostate volume is widely employed as the determinant for deciding on 
whether to treat a man with symptomatic Benign Prostatic Hyperplasia 
[32].
3.2 Meta-anafysis o f Other Treatments fo r Benign Prostatic Hyperpiasia
104. The leading types of pharmaceutical treatments for BPH are five 
alpha-reductase inhibitors (such as finasteride and dutasteride) and 
alpha-blocker (such as terazosin, doxazosin). In many countries 
Permixon, a drug made from plant extracts, is widely employed. Apart 
from pharmaceutical treatment, surgery and trans-urethral needle 
ablation are common forms of treatment.
3.2.1 Meta-analysis of Terazosin
105. Alphai-adrenergic antagonists have been widely used in the 
treatment of men with lower urinary tract symptoms (LUTS) suggestive 
of benign prostatic hyperplasia (BPH). A high density of alpha receptors 
has been demonstrated in the areas of the bladder neck, the prostatic 
capsule and the prostate tissue itself. Furthermore, it has been 
demonstrated that while in young men the ration between stromal and 
glandular-epithelial tissue in the prostate is about 2:1, it changes with 
advancing age and the development of BPH and associated symptoms 
in favour of the stromal component to a ratio of approximately 5:1. 
Blockade of ai-receptors inhibits smooth muscle contraction and 
decreases muscle tone in the prostate. Consequently urethral pressure 
and resistance are decreased thereby reducing bladder outlet
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obstruction. Thus, the use of ai-receptors antagonists such as 
terazosin would be expected to be effective in men with a high density 
of prostatic smooth muscle.
106. On the available alpha-blockers, terazosin has most extensively 
been studied in men with LUTS and clinical BPH. In large, double-blind 
placebo-controlled trials and long-term open studies, it has been found 
to significantly improve the symptoms of BPH and to increase peak 
urinary flow rate (Q m ax) compared with baseline and placebo, in a semi- 
quantitative overview, noted that symptom improvement with terazosin 
appeared to be dose dependent and the (higher) dose of 10 mg 
ameliorated obstructive, irritative and total symptom scores to a 
significantly greater extent than placebo. Qmax increased by between
1.5 to 4 ml/sec. in men treated with terazosin, representing a 20-40 
percent increase which was generally 2-fold higher than the change 
seen with placebo.
107. Terazosin appears to be effective for LUTS within a few weeks and 
it has been speculated that men with low Qmax, moderate to severe 
symptoms, a predominance of obstructive symptoms or a high density 
of prostatic smooth muscle may predict a positive response to 
terazosin.
108. A meta-analysis of all clinical trials was undertaken to determine the 
effectiveness of the long-acting alpha-1 adrenergic receptor blocking 
agent terazosin compared to placebo therapy on lower urinary tract 
symptoms and peak urinary flow rate in men with clinical benign 
prostatic hyperplasia. The aims of the study included to determine 
whether or not the results reported in the literature are heterogeneous, 
and to determine whether baseline prostate volume influences the 
outcomes.
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109. Original data on ail patients from nine placebo-controlled 
randomized trials of varying duration comparing terazosin and placebo 
were obtained. A formal meta-analysis using an Empirical Bayes' [33] 
approach and a further employing a fully Bayesian approach were 
conducted. The primary endpoints of these studies were changes in 
peak urinary flow rate and urinary symptom scores from baseline to 
end of study. A further pooled analysis was conducted on those studies 
in which patients had a baseline assessment of prostate volume by 
transrectal ultrasonography [33].
110. There was no evidence of heterogeneity in the estimated effects of 
terazosin on the change in peak flow rates over the studies [33]. 
Terazosin treatment Is associated with an increase of peak flow rate of
1.4 ml/sec (95% Confidence Interval (C.I.) (1.0, 1.7)) greater than the 
change in the placebo group. In terms of the change in the common 
symptom score (ranging from 0 to 35 points), terazosin resulted in an 
average reduction of 2.2 points over and above the placebo effect 
(95% C.I. (1.6, 3.0)). There is some evidence that there is mild 
heterogeneity across the studies, with regard to changes from baseline 
in the common symptom score associated with the duration of 
treatment, the decrease in symptom being slightly greater on longer 
treatment duration. There is a tendency for a greater effect to be seen 
at higher doses although this is difficult to interpret unambiguously. 
There was no evidence that the effect of Terazosin was influenced by 
baseline prostate volume [33].
111. Terazosin is effective in reducing lower urinary tract symptoms and 
increasing peak urinary flow rate in men with clinical BPH. The effect of 
terazosin appears to be greater in studies of longer duration (up to 1 
year) although the effect on peak urinary flow rate is apparent in 
studies as short as eight weeks. Most importantly, the effect of 
terazosin on symptoms and peak urinary flow rate is independent of
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baseline prostate size over the range of prostate volumes reported in 
the nine studies [33].
3.2.2 Meta-analysis of Permixon
112. Permixon® is a standardised lipido-sterolic extract of Serenoa 
repens. Its major mechanism of action is still uncertain; however 
several activities have been demonstrated. It repeatedly exerts anti- 
androgenic activity in the form of a non-competitive inhibition of 5 
alpha-reductase type I and type II, resulting in a decrease in prostatic 
dihydrotestosterone content In BPH patients treated with this 
compound. Permixon® also appears to inhibit in vitro b-FGF and EGF- 
induced prostate epithelial cell proliferation and decreases EGF 
concentration in human prostate. It also exerts an anti-inflammatory 
effect through the inhibition of the enzymes responsible for 
prostaglandin, and leukotriene, synthesis.
113. Permixon® is extracted from the fruit of the American dwarf palm 
tree, Serenoa repens, which is widely used in the treatment of men 
with lower urinary tract symptoms (LUTS) suggestive of benign 
prostatic hyperplasia (BPH). There is significant controversy regarding 
the use of phytotherapeutic agents in such men. The purpose of this 
meta-analysis is to analyze all available clinical trial data of the 
Permixon® preparation to determine its clinical efficacy in comparison 
versus placebo.
114. All clinical trial data published on Permixon® were made available 
and utilized in the analysis [34]. Eleven randomized clinical trials and 
two open label trials comprised the database. These trials were 
disparate in size (from 22 to 592 patients) and duration (from 21 to 
180 days). There were thirteen studies involving 2859 patients: 1961 
on Permixon®, 278 on placebo, 545 on finasteride, 31 on alfuzosin, 22
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on prazosin and 20 on an extract of pygeum africanum (Tadenum). 
Eleven studies had information on peak urinary flow and although 
widely different symptom scores were used in the trials, each had 
information on nocturia. The statistical analysis was based upon a 
random effects meta-analysis [34].
115. A random effects meta-analysis model was used where the studies 
were treated as the random effects [34]. For the majority of studies 
there were two observations: the response on placebo and the 
response on Permixon®. Some studies had three groups and in other 
the placebo was replaced by a comparator drug. The basic statistical 
model contained a term for the average response in each study, 
corresponding to effect of placebo, and terms comparing the other 
compounds to placebo, the treatment effects.
116. There was evidence of significant variation over the studies in the 
average response but no extra variation in the treatment effects. As 
the treatment effects represent deviations from the placebo effect if 
there is random variation in the placebo effect then there will be the 
same random variation in the treatment effects also. An attempt to try 
to investigate the between study heterogeneity was carried out using 
fixed effects known to differ over the studies. These included study 
type (randomized versus open label), dose of Permixon® and duration 
of study, but none was found to be important.
117. Over all the trials, the average placebo effect upon peak urinary 
flow rate was an increase of 0.94 (s. e. 0.49) ml/sec [31]. The 
estimated effect of Permixon® is a further increase of 1.87 (s. e. 0.55) 
ml/sec (p < 0.001). There is no evidence of significant heterogeneity 
over studies in this effect, and study length (treatment duration) does 
not appear to impact on this effect. Placebo was associated with a 
reduction in the mean number of nocturnal urinations of 0.66 (s. e.
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0.24). There is a further reduction attributable to Permixon® of 0.55 (s. 
e. 0.10) episodes of urination (p < 0.001). There is some heterogeneity 
present which cannot be explained by differences in treatment 
duration.
118. Despite limitations in the information provided by some clinical trials 
and the need for caution in Interpreting their findings, there does 
appear to be strong evidence that the use of Permixon® increases 
peak urinary flow rate in a consistent manner across studies and this is 
confirmed as a highly significant effect over placebo in the meta­
analysis [34]. This meta-analysis of all available published trials of 
Permixon® in the treatment of men with BPH reveals a significant 
improvement in peak flow rate and reduction in nocturia above placebo 
[35]. This of considerable interest but one conclusion which could be 
drawn from this meta-analysis was the clear need for more studies with 
BPH Symptom Score endpoints.
3.2.3 Update meta-analysis of Permixon
119. Following publication of several large studies, including two 
randomised trial with a complete Symptom Score available, an updated 
meta-analysis of Permixon was undertaken [35].
120. All clinical trial data published on Permixon® comprising 14 
randomized clinical trials and 3 open label trials, involving 4280 
patients, were utilized. These trials were disparate in size (from 22 to 
1100 patients) and duration (from 21 to 720 days). Peak urinary flow 
and nocturia were the two common endpoints. The statistical analysis 
was based upon a random effects meta-analysis [35].
121. Permixon® is associated with a reduction in IPSS of 4.78 (s.e. 
0.41). The average placebo effect upon peak urinary flow rate was an
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increase of 1.20 (s. e. 0.49) ml/sec. The estimated effect of Permixon® 
is a further increase of 1.02 (s. e. 0.50) ml/sec (p =0.042). Placebo 
was associated with a reduction in the mean number of nocturnal 
urinations of 0,63 (s. e. 0.14). There is a further reduction attributable 
to Permixon® of 0.38 (s. e. 0.07) episodes of urination (p < 0.001). 
There is some heterogeneity over studies for nocturia. One study over 
2 years involving 396 patients and showing no difference between 
placebo and Permixon® has a large impact on the results [35].
122. This meta-analysis of all available published trials of Permixon® in 
the treatment of men with BPH reveals a significant improvement in 
peak flow rate and reduction in nocturia above placebo and a five-point 
reduction in IPSS [35].
3.2.4 Meta-analysis of Trans-Urethral Needle Ablation (TUNA)
123. Clinical Benign Prostatic Hyperplasia (BPH) is a progressive 
condition which affects a large proportion of men in the community. If 
left untreated it can lead to potentially serious complications including 
acute urinary retention, recurrent urinary tract infections and bladder 
calculi. Therapeutic interventions include medical management and 
intervention either surgically or with minimally invasive treatments. 
Transurethral Needle Ablation (TUNA) utilizes radio-frequency energy 
to heat prostate tissue. In order to investigate short- and long-term 
effectiveness, a meta-analysis of all clinical studies conducted on TUNA 
has been performed [36].
124. Data were abstracted from two randomised trials, two non­
randomised observational protocols and seven single arm studies 
conducted on TUNA according to a determined protocol. As we have 
used before, the meta-analysis was based on the change in the mean 
score from baseline to the end of study. The estimation of the effects
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from the meta-analysis used a multilevel model including random 
effects for the studies [36].
125. In all studies the patients recruited had severe LUTS with a mean 
IPSS score around 20 or more prior to treatment. The effect of TUNA 
was to halve the mean IPSS score one year after treatment (mean 
change 12.1 points) and although there was a slight tendency for IPSS 
to increase in all arms from year 1 to year, 5, this 50% decrease was 
maintained at five years. Qmax also increased by around 70% from 
baseline to year 1 (mean improvement 5.1 ml/s) and in virtually all 
studies the mean Qmax approached or exceeded 15ml/s. Although 
there was a tendency for Qmax to slightly decline with time since 
treatment, mean Qmax five years after treatment was still over 50% 
higher than at baseline [36].
126. This meta-analysis has demonstrated that Transurethral Needle 
Ablation of the prostate is an effective and minimally invasive 
treatment for men with clinical BPH, even when symptoms are severe. 
There is a large improvement in symptoms and flow rate after one 
year, which persists until five years, and is only slightly less than that 
achieved by TURP. TUNA therapy would appear to be an alternative to 
surgery and also an attractive option for men who do not wish long­
term medical therapy, or who are poor candidates for surgery or 
concerned about the side effects of TURP [36].
3.3 Summary and Conclusions: Evidence-based Approach to Treatment 
Evaiuation in BPH
127. The initial meta-analysis of finasteride [22] has had a significant 
impact on how patients with lower urinary tract symptoms are treated 
as well as in the wider context of how the urological community 
considers BPH and LUTS. Patients with large prostates are generally 
directed towards a five-alpha reductase inhibitor (such as finasteride)
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and those with small prostates are targets for alpha-blocker therapy 
(such as doxazosin).
128. The importance of prostate volume as a predictor of outcome of 
therapy [22] and the demonstration that serum PSA could predict 
outcome as well as the invasive Trans Rectal Ultrasound and MRI 
estimation [23, 24], has been a further aid to determining treatment 
choices [32]. The demonstration that finasteride therapy, and 
subsequently dutasteride therapy, could lead to a reduction in the risk 
of acute urinary retention [28] is a further addition to improvement in 
the quality of life of ageing men as is the ability to make a probability 
assessment of which men are at high risk of AUR [31].
129. The effect of the alpha-blocker, terazosin, on prostates of all sizes is 
of considerable interest [33] although more long-term data are 
required from all alpha-biockers. The demonstration of the efficacy of 
Permixon, particularly the magnitude of the improvement in flow rates, 
is another addition to the treatment options for men with urinary 
symptoms [35, 36].
130. The meta-analysis of TUNA has demonstrated the effectiveness of 
this therapy among men with severe symptoms and having the same 
effect as surgery in men with similar symptoms [32].
131. Thus, these meta-analyses have contributed significantly to helping 
improve the outcome of therapy of men with LUTS or BPH by helping 
select the right patients for the right treatment. Their importance is 
reflected by their impact in the available treatment guidelines from 
associations around the world [32].
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4 Renal Dialysis and Cancer Risk
132. Although kidney transplantation is an effective treatment for end- 
stage renal disease (ESRD), dialysis is still the commonest treatment 
for such patients. Patients maintained on dialysis are potentially at 
increased risk of cancer for several reasons, including: the presence of 
chronic infection, especially in the urinary tract; a weakened immune 
system; previous treatment with immunosuppressive or cytotoxic 
drugs; nutritional deficiencies; and altered DNA repair. In addition, the 
underlying disease leading to renal failure, the persistent metabolic 
changes associated with it, and the development of certain 
complications, such as acquired renal cystic disease, may predispose to 
cancer.
133. Certain types of genitourinary disease are known to predispose to 
renal or urothelial tumours. For example, the risk of renal cancer is 
known to be increased in patients with inherited or acquired cystic 
disease of the kidney. Patients with Balkan nephropathy and analgesic 
nephropathy have a high risk of tumours of the renal pelvis and 
ureters. Although the increased risk of cancer after renal 
transplantation is well documented, there is less certainty about the 
risk of cancer in patients treated only with dialysis. Most of the 
reported studies are too small to detect potentially important findings 
on less common types of tumours or small increases in risk, or to study 
the relation between cancer and the various causes of renal failure or 
the method of dialysis treatment. By studying several hundred 
thousand patients with ESRD, we hoped to overcome some of these 
deficiencies.
4.1 Cancer In Renal Dialysis in Lombardy Region, Italy
134. The risks of primary cancers among patients who have been the 
recipients of a renal graft are known; there has been relatively little
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investigation of patients who received long-term renal dialysis. There 
appears to be excess of renal-cell cancer characterised by being a more 
aggressive form of the disease. Reports of excesses of non-Hodgkin 
lymphoma have not always been confirmed. We obtained data from 
the Lombardy Regional Dialysis and Renal Transplant Registry. All 
patients on file during 1982-93 had complete demographic information 
and medical history. Patients with a history of cancer or who developed 
cancer during the first year of dialysis were excluded and only the first 
cancer was considered. 44,023 patient years were available for the 
study, 25,684 in men and 18,339 in women [37].
135. 479 cases of cancer at all sites was recorded. The average age at 
diagnosis was 59.5 years and the cases were on dialysis for an average 
of 6.37 years. There were statistically significantly raised risks of 
primary iiver cancer, kidney cancer, thyroid cancer, lymphoma, and 
multiple myeloma. There were significantly decreased risks of cancers 
of the oral cavity and larynx, and a non-significant decrease in cancer 
of the oesophagus [37]. The excess of non-Hodgkin's lymphoma is 
similar to that found in recipients of renal transplants. The excess of 
liver cancer might be linked to materials used during dialysis.
136. Longer and better survival of patients with end stage renal disease 
undergoing renal replacement therapy means that there are many 
elderly patients receiving therapy. Our results highlight the need for 
careful follow-up and for early detection of cancers in these patients 
[37]. In addition, these findings were used in the context of a pilot 
study to demonstrate what would be the issues in putting together 
similar datasets on the same topic.
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4.2 Cancer in patients on dialysis for end-stage renal disease: an 
international collaborative study
137. The study described above [37], limited to one geographic region 
and a resultant limitation of cases of different forms of cancer, served 
as a pilot for a major study designed to give a clearer insight into the 
potential association between renal dialysis and the subsequent risk of 
developing cancer. We obtained previously stored data from dialysis 
registries in three continents: the US Rena! Data System, the European 
Dialysis and Transplant Association and the Austraiia and New Zeaiand 
Diaiysis and Transpiant Registry, The Australia and New Zealand 
registry, although much smaller than the other two, was the only one 
with a uniform mechanism of reporting to the central registry for the 
diagnosis of cancer, and with complete, population-based information 
on dialysis. In view of possible variations in population coverage of 
dialysis and the completeness of coverage of cancer follow-up between 
the three registries, findings are presented separately for the three 
registries. This approach also allows the similarity of the findings in the 
three registries to be taken into account in interpretation of the data.
138. The data from Australia and New Zealand are the most complete in 
terms of both coverage and follow-up, although it is the smallest 
dataset. The US dataset is the largest and is also largely complete for 
coverage of patients on dialysis, although not necessarily for cancer 
follow-up. The European registry is of intermediate size; it has the 
lowest coverage and is likely to have the least complete cancer follow- 
up. We emphasise that these factors must be borne In mind in 
interpretation of the findings from this study and that the real strength 
of the approach taken to data analysis lies In the replication of findings 
between the registries [38].
139. The cohort consisted of patients in the three registries who 
underwent dialysis during the period 1980-94. We retrieved the
56
following Information from the computerised databases: demography 
(country, region or state, date of birth, sex, and ethnic group); the 
cause of renal failure; treatment (date started, date of death or 
transplantation, type of dialysis); and diagnosis of cancer (date and 
type). We excluded patients with missing data on date of birth or 
follow-up; those treated in regions for which suitable background 
cancer rates were not available; those in whom the diagnosis of cancer 
preceded dialysis or in whom cancer treatment was the cause of renal 
failure; all those who received dialysis after transplantation; and those 
with AIDS. We excluded from the cancer analysis benign tumours, non­
melanoma skin cancers, and metastatic cancers. All cancers were 
coded according to the ninth edition of the International Classification 
of Diseases (ICD9).
140. Because the classification of primary renal diseases in the three 
registries shows some differences, we reclassified the primary renal 
diseases into ten major groups: arteriopathic diseases; 
glomerulonephritis; diabetes; infective and obstructive nephropathy; 
congenital diseases; familial and hereditary diseases; toxic 
nephropathy; neoplasms; miscellaneous disorders; and uncertain 
cause.
141. For the USA, we calculated background cancer rates from the 
Surveillance, Epidemiology, and End Results Program of the National 
Cancer Institute. Cancer incidence rates specific for age, sex, and race 
were calculated for all the Surveillance, Epidemiology, and End Results 
registries for each year from 1980 until 1994. In Europe, and in 
Australia and New Zealand, we used published rates for two periods 
around 1985 and 1990, respectively. We used country-specific cancer 
data if they were available. If national data were not available, we 
substituted data from regional registries. For countries without cancer 
incidence data, we substituted data from neighbouring countries.
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142. For the Australia and New Zealand dataset, we identified ESRD 
patients with cancer directly from previously coded cancer data In each 
patient's computerised file. We verified the diagnosis of cancer through 
record iinkage for patients treated in New South Waies, the Australian 
state with the highest population; 33*5% of the patients in this dataset 
were drawn from New South Wales, which has had a population-based 
cancer registry in operation since 1971. In this group, the Australia and 
New Zeaiand registry had recorded 228 cancers, whereas 221 cancers 
were recorded with the New South Waies Central Cancer Registry. For 
200 (88%) of the 228 tumours, there was a close match on date of 
birth, date of diagnosis, and tumour type. For the US ESRD patients, 
the diagnosis of cancer depended on submission of reimbursement 
forms for hospital admission, which contained information about cancer 
diagnosis or treatment. For Europe, individual treatment centres 
submitted data on the presence or absence of cancer, but there was no 
standard cancer-reporting mechanism.
143. For patients who were alive at the end of the study period, we 
calculated the number of person-years at risk from the date of first 
dialysis until the end of the study period. Patients who had undergone 
transplantation were censored at the time of the operation. For 
patients who died during the study period we counted person-years 
from the start of dialysis until death. We calculated expected numbers 
of cancers by multiplying the number of person-years accumulated in 
each stratum of age, sex, race, country, and calendar time by the 
corresponding background specific rate. The standardised incidence 
ratio (SIR; the ratio of observed to expected cancers) was used to 
estimate the relative risk. 95% Cl for these ratios were calculated with 
the assumption that the observed number of cancer cases followed a 
Poisson distribution.
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144. The original datasets contained information on 963 250 patients.
iWe excluded 131 446 patients in total: 24 014 with no available 
background cancer rates; 40 8:^ 0 who started dialysis before 1980; 16 
024 with missing data on date |of birth or follow-up; 47 866 who had 
previously had cancer or whose primary renai disease was caused by 
cancer or amyloidosis; 1963 with AIDS; and 749 with renai failure that 
occurred after transplantation. |rhe final cohort therefore consisted of 
831 804 patients undergoing treatment for ESRD followed up for a 
mean of 2*5 years until last visit, transplantation, or death. The mean 
duration of follow-up ranged frcjm 2 2 years in the USA to 2*9 years in 
the European registries, resultirig in more than 2 million person-years 
of follow-up data. 110 110 patients were followed up for 5 years or 
longer and 15 825 for 10 yearjs or longer. The mean age at start of 
dialysis differed in the three registries: patients treated in Australia and 
New Zealand were on average 9^ years younger than those treated in 
the USA; patients in Europe were intermediate in age. In each of the 
registries there were more male (55’2%) than female patients [38].
145. The frequency of known underlying causes of renal failure during 
the study period differed between registries [38]. In Australia and New 
Zealand, glomerulonephritis was the commonest cause of renal failure 
(35-5%), followed by diabetes; and toxic nephropathies. In Europe, 
infective and obstructive nephropathies were the most frequently 
defined diagnosis (16-2%); in the USA, diabetes was the commonest 
underlying disease (32-8%), followed by arteriopathic diseases 
(including hypertension) and glomerulonephritis. The distribution of 
underlying renal disease differed substantially between younger and 
older patients. In particular, glomerulonephritis (31%), infective 
obstructive nephropathy (12%), and congenital disorders (3%) were 
over-represented in the younger patients. The cause of the primary 
renal disease was missing or uncertain for more of the European 
patients than for the other cohorts [38].
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146. During the study period, 25 044 primary cancers (non-melanoma 
skin tumours excluded), were recorded compared with 21 185 
expected (SIR 1'18 [95% Cl 1'17-1'20]). The excess of cancer was 
greatest in Australia and New Zealand (1’8 [1'7-2'G]) and lower in 
Europe (1*1 [ I 'O - l ' l ] )  and in the USA (1"2 [1'2-1'2]). The proportion 
of patients with recorded cancers was 2*3% in Europe, 3'4% in the 
USA, and 3'7% in Australia and New Zeaiand. The risk of cancer was 
particularly high in the youngest age-groups (3'68 [3'39-3'99]); rates 
in the elderly were only slightly, if at all, increased [38].
147. To see whether the results were due to increased detection of 
cancer at the time of initial dialysis treatment (ascertainment bias), we 
analysed the findings in relation to the number of years since start of 
dialysis. Although the risk of cancer was slightly higher when cancer 
was diagnosed during the first year of diaiysis (except in the USA), 
exclusion of the first year of follow-up from the analysis did not change 
the overall results. We also looked at risk of cancer in relation to the 
type of dialysis treatment: haemodiaiysis, peritoneal dialysis, or both 
types. We found no differences in the risk of cancer associated with 
these categories. In analyses of the relation between cancer and the 
underlying renal disease, the highest risk ratios were seen in patients 
with toxic or infective and obstructive nephropathies, and in the small 
group of patients with congenital kidney diseases.
148. We observed high cancer risks in several subsites. The number of 
tongue cancers reported was almost twice that expected. The risk of 
liver cancer was raised in several types of primary renal disease, but 
particularly in patients with diabetes. There were more cancers of the 
cervix, but not the body of the uterus, than expected. Vulvovaginal 
(n=112) and penile cancers (n=55), although rare, were about 1'8 
times more common than in the background population. Thyroid and 
other endocrine tumours were more than twice as common in the
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ESRD population as In the background population (2'28 [2 ‘03-2*54]). 
There was an increased risk of various types of haemopoietic tumours, 
especially multiple myeloma. An increase in cancer was observed at 
some sites that are commonly involved in metastatic cancer, such as 
peritoneum (ICD9 158), other respiratory sites (ICD9 164-165), and 
bone (ICD9 170) [38].
149. High risks were observed for cancer of the bladder (1'50 [1 ’42- 
1'57]) and kidney (3'60 [3'45-3 76]). For both sites, rates were higher 
in younger than in older patients, and in those with toxic or infective 
and obstructive nephropathies than in those with other types of renal 
disease. There was little variation in the relative risk of bladder cancer 
with increasing time on dialysis [38], although duration of dialysis 
seemed to influence the relative risk of kidney cancer [38].
150. In agreement with several previous reports, our study shows an 
overall increased risk of cancer in ESRD patients; the risk was highest 
in Australia and New Zealand, and lower in Europe and in the USA. On 
the basis of the method used for ascertainment of cancer and the 
validation study carried out in the ESRD patients in New South Waies, 
we believe that the higher cancer rates observed in Australia and New 
Zealand reflect more accurate reporting of cancer in these patients. 
Because ascertainment of cancer in the other two registries was less 
rigorous, our report almost certainly underestimates the risk of cancer 
in European and US ESRD patients. In Europe, when we restricted the 
analysis to countries known to have high-quality cancer data (ie, the 
Scandinavian and Benelux countries), the observed cancer risks were 
similar to those in Australia and New Zealand.
151. Significantly increased cancer risks were seen in younger ESRD 
patients, and for several sites of cancer, such as the kidney and 
bladder, as well as the tongue, iiver, lower genital tract in women,
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external genitalia in men, the thyroid, lymphomas, and multiple 
myeloma. The high risk of cancer In younger ESRD patients, detected 
in all three registries, is an unexpected finding, which was not included 
in the list of prior study hypotheses. In comparison with the 
background population, the excess cancer risk was highest in the 0-34 
year age-group, gradually declined with increasing age, and almost 
disappeared in patients in the oldest age-groups.
152. This age-related pattern has not been reported in previous studies, 
perhaps because most have been too small to include sufficient 
numbers of patients in younger and older age-groups. We do not 
believe that data entry errors explain the findings because In the USA 
we verified the age at diagnosis of cancer in patients younger than 35 
years from original records, and in New South Wales patients, we 
found no errors in recorded year of birth. The excess risk in these 
younger patients was especially prominent for cancers of the kidney 
and bladder, and in patients with renal failure of infective, obstructive, 
congenital, or miscellaneous cause, but it occurred at many sites and 
with most primary renal diseases.
153. Between 13% (USA) and 25% (Australia and New Zealand) of the 
cancers occurred in the kidney or bladder, sites at which the nature of 
the primary kidney disease or associated urological abnormality, or the 
development of acquired renal cystic disease, may be the underlying 
cause. These increased risks are related to age and to primary renal 
disease. Cancer of the kidney but not that of the bladder was 
associated with duration of dialysis.
154. Certain tumours developing in ESRD patients before and after 
transplantation may share common risk factors. Viruses have been 
suggested as causative agents for some of the tumours in those sites. 
Viral infections occur in about 10% of patients after transplantation;
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further studies are needed to assess the frequency of viral infection 
and the relation between viruses and cancer at these sites in ESRD 
patients.
155. The fact that ESRD patients have greater than normal exposure to 
hepatitis B and C viruses probably accounts for the observed excess of 
liver cancer. We found an excess of liver cancer in the diabetic ESRD 
group, as has been reported in diabetic patients with normal kidney 
function; however, overall, diabetes was the primary renal disease with 
the least increased risk of cancer in this study. The human 
papillomavirus has been linked to cancers of the tongue, cervix (but 
not the body of the uterus), vagina, vulva, and penis. Activation of 
dormant Epstein-Barr virus, which is associated with some lymphomas, 
is likely to explain the increased risks for these tumours in renal-dialysis 
patients and transplant recipients [38].
156. There is no explanation for the increased risk of thyroid and other 
endocrine tumours (ICD9 193-194) which was observed in all three 
registry populations. Ascertainment bias, through the repeated 
examination and imaging of the neck in relation to the diagnosis and 
management of secondary hyperparathyroidism, may have contributed, 
because the frequency of thyroid tumours rose with duration of 
dialysis.
157. Since the risk of cancer was not related to the type of dialysis, we 
deduce that the uraemic state, rather than any treatment-related 
phenomenon, is likely to be the cause of the increased risk.
158. There are several potential sources of bias in this study, all of which 
serve to produce conservative estimates of the relative risks. Closer 
surveillance of ESRD patients than of the general population could 
explain some of the excess cancer risk. We may not have excluded all
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patients with prevalent cancers from the cohort. This possibility is one 
potential explanation of the large excess of multiple myeloma, which 
may have been the cause of the ESRD, soon after the start of dialysis. 
Unrecognised urothelial cancer as the cause of obstructive ESRD is 
unlikely to account for more than a fraction of the increased risk of 
bladder cancer. Because of the large size of the dataset, small 
differences in outcome will be significant; and with multiple endpoints, 
some positive results are likely to be chance findings. However, many 
of the associations identified in this study have been reported 
previously.
159. The findings of this study raise the question of the correct approach 
to cancer screening in ESRD patients. One previous study suggested 
that cancer screening may be an inefficient allocation of resources, 
adding little to life expectancy in these patients. Although we agree 
with this observation as it applies to the generality of ESRD patients on 
dialysis, our findings of substantially increased risks in younger 
patients, and in relation to specific organs, suggest that a selective 
approach to cancer screening and detection may be an appropriate 
research priority. It is difficult to attribute the large increased relative 
risks of cancer in younger patients, seen consistently in all three 
cohorts, to the effects of bias. There is no active screening of such 
patients for cancer, which could explain any of the observations. In 
future studies of younger patients, particularly those with bladder or 
kidney cancers, information on stage of disease at diagnosis and death 
would be very useful, although it might be very difficult to interpret 
[38].
160. Differences in the classification of the primary renal disease (PRD) 
used in different renal dialysis and transplant registries worldwide is 
noteworthy [40]. The heterogeneity of coding systems complicates the 
comparative analysis of end-stage renal disease from different regions.
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Using data collected over two decades in the United States, Europe, 
and Australia/New Zealand, we present a method for reorganization of 
the classes of PRD that allows a straightforward comparison of 
retrospective data from these registries [39].
161. Using this classification enables use to be made of the large 
resource to investigate specific associations between underlying kidney 
disease and risk of specific forms of cancer. Patients on maintenance 
dialysis have increased risk for cancer, especially in the kidney and 
urinary tract. In this retrospective cohort of 831,804 patients starting 
dialysis during 1980 to 1994 in the United States, Europe, or Australia 
and New Zealand, standardized incidence ratios (SIR) with 95% 
confidence intervals (Cl) were calculated for kidney and bladder 
cancers [40].
162. Risks for cancers of the kidney (SIR 3.6; Cl 3.5 to 3.8) and bladder 
(SIR 1.5; Cl 1.4 to 1.6) were increased, relatively more in younger than 
older patients and more in female patients (kidney: SIR 4.6, Cl 4.3 to 
4.9; bladder: SIR 2.7, Cl 2.4 to 2.9) than male patients (kidney: SIR 
3.2, Cl 3.0 to 3.4; bladder: SIR 1.3, Cl 1.2 to 1.3). SIR for kidney 
cancer were raised in all categories of primary renal disease, and for 
bladder cancer in all but diabetes and familial, hereditary diseases. 
Notably high SIR occurred in toxic nephropathies (chiefly analgesic 
nephropathy) and miscellaneous conditions (a category that includes 
Balkan nephropathy), the excess of kidney cancer in these conditions 
being urothelial in origin. SIR for kidney cancer rose significantly, and 
those for bladder cancer fell (not reaching significance) with time on 
dialysis. There was no association with type of dialysis [40].
163. The pattern of increased risk for renal parenchymal cancer in 
dialysis patients is consistent with causation through acquired renal
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cystic disease and of urothelial cancers of the kidney and bladder with 
the carcinogenic effects of certain primary renal diseases [40].
Urological Cancers
164. Urological cancers represent a substantial proportion of cancers in 
men and women. Currently there are over 160 population-based cancer 
registries providing cancer incidence data of recognisably high-quality: 
the most recent data available cover the period around the mid-1980s. 
Out of a total of 3,618,375 cancer cases (non-melanoma skin cancers 
are excluded from virtually all registries) registered in men in these 
three registries, during the years covered by this volume, there were 
221,033 bladder tumours (6.1% of all cancer in men); 92,064 kidney 
cancers (2.5%); 445,1346 prostate cancers (12.3%); 38,462 testicular 
cancers (1.1%); and 9,036 cancers of the penis (0.26%) . In other 
words, 22.3% of all incident cancers in men world-wide occur at 
urological sites [41].
165. In women, there were a total of 3,351,605 incident cases of cancer 
in the same populations. Of these 77,220 were bladder cancers (2.24% 
of all cancers in women) and 59,655 were kidney cancers (1.7%). A 
total of 4% of all cancers in women were of urologie origin.
166. Some urologie cancers are relatively more frequent than others In 
different population groups. In men, bladder cancer represents 58.3% 
of all urologie cancers in Shanghai, China but only 10,2% of such 
cancers in Afro-Americans in the United States SEER (Surveillance, 
Epidemiology and End Results) Programme registries. In Afro-American 
men, prostate cancer represents nearly 80% of urologie cancers while 
only 14.7% of urological cancers in Shanghai. Kidney cancer represents 
less than 105 of all urologie cancers in North America and the United
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Kingdom but one-quarter of all urologie cancers In Warsaw, Poland. 
Testicular cancer is more homogeneous except for a relatively low 
proportion among Afro-American men. Despite being relatively rare in 
most western populations, cancer of the penis still accounts for over 2 
per cent of urologie cancers in Chinese populations [41].
167. In women, urologie cancers range between 3 and 5 per cent of all 
cancers world-wide and kidney cancer is between 1 and 2 per cent. 
There is little variation, although it is interesting to note that over 5 per 
cent of all cancers in Danish women are urologie in origin with both 
bladder and kidney cancer relatively high. However, it is difficult to 
ignore that urological cancers compromise a large proportion of the 
total cancer burden worldwide [41].
5.1 Testicular Cancer Outcome
168. Chemotherapy has been long used in the treatment of testicular 
cancer. Li and colleagues, in 1960, employed chlorambucil, actinomycin 
D and methotrexate to obtain seven responses out of 23 patients: 
three patients remained well for periods of between 9 and 18 months. 
Mackenzie, in 1966, reported that among 154 patients with advanced 
testicular cancer, that actinomycin D was the most active single agent 
for the treatment of teratomas. Other studies from the same era 
demonstrated that other agents were also useful: vinblastine sulphate, 
mithramycin, bleomycin, imidazole carboxamide, and adriamycin.
169. In 1976, Tim McElwain, writing in Symington's seminal book 
Scientific Foundations o f Oncology, summarised the current state of 
knowledge of the treatment of testicular cancer. He concluded that 
chemotherapy had little place in the management of seminoma, a 
tumour so radiosensitive that it can be usually controlled by 
Radiotherapy. However, chemotherapy was more important in the
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treatment of teratomas since over half of patients present with (or later 
develop) widespread métastasés and such tumours are much less 
radiosensitive than seminomas. He did acknowledge that "responses 
to chemotherapy are often transitory and it is doubtful if life is 
always prolonged in responders".
170. Remarkable progress has been made since then with survival rates 
increasing from around 10% in the 1970s to 90% in the 1990s with 
much of the improvement attributable to the development of 
chemotherapy schedules based on cisplatinum, (first established by 
Larry Einhorn and John Donohue in 1977) and a realisation of the 
importance of combined management of such patients.
171. Using incidence and mortality data until 1983, Boyle et al in 1987 
[42] showed a decline in mortality in Scotland from testicular cancer 
following the demonstration of effective therapy (in 1977) even against 
a background of increasing incidence. Since then incidence has 
continued to increase in Scotland while mortality has continued to 
decline. Similar patterns have been recorded in a number of countries 
including Denmark, Poland and England and Wales.
172. The decline in mortality rates from testicular cancer was evident in 
nearly all countries between 1975 {pre-platinum) and 1985 {post- 
piatinum) with large decreases in the relative risk of death apparent 
almost everywhere. In 1990, Kaye and Boyle [43] were able to 
conclude that "it is widely appreciated that the application of 
chemotherapy in the treatment of germ cell tumours exemplifies the 
best results to be expected from this approach to solid tumours, since 
the majority of patients treated are now cured." 80-90% of patients 
with testicular cancer could expect to be cured of their disease and in 
most countries this seemed to be so, but not in Central and Eastern 
Europe where about 1 in 2 cases may die of their disease. Any
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fundamental difference in biological behaviour is unlikely and a more 
likely explanation is that the differences in mortality relate to delivery of 
curative chemotherapy, including cisplatin, or to deficiencies in patterns 
of referral [42].In the West of Scotland, a clinical audit was conducted 
on 440 (97%) of 454 men diagnosed with non-seminomatous germ cell 
tumours (NSGCT) between 1975 and 1989. Independent prognostic 
factors identified were extent of tumour at diagnosis (p<0.001), five- 
year time period of diagnosis (p<0.001) and treatment unit (the largest 
treatment unit compared to the four others)( p<0.001). This unit 
treated the majority of patients (53%), including the majority in the 
worst prognosis group (70% were poor-prognosis metastatic disease). 
In this unit, 97% of men received treatment according to the national 
protocol compared to 61% elsewhere (p<0.0001). When analysis was 
restricted to those men who protocol treatment, after adjustment for 
other prognostic factors, those men treated in other units had a 
Relative Risk of death of 2.8 (95% C.I. 1.53, 5.19) compared to the 
largest unit. This unit is characterised by having men assessed at a 
joint multidisciplinary clinic. These findings contain the clear message 
that specialisation and centralisation of treatment for non- 
seminomatous germ cell tumours improves outcome, the benefit being 
over and above the advantage resulting from protocol treatment.
174. Boyle, Maisonneuve and Kaye [44] speculated that the poor 
outcome from testicular cancer could be related to the lack of financial 
resources to purchase the expensive drugs necessary to treat 
disseminated testicular cancer. The economic situation in many of 
these countries has been changing rapidly including in Slovakia, where 
there has been an effective population-based Cancer Registry for many 
years making comparison of trends in incidence and mortality from 
testicular cancer possible. Another interesting aspect of testicular 
cancer treatment in Slovakia has been the establishment in 1982 of a 
specialist treatment centre for non-seminoma testicular cancer in the
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Department of Urology in the School of Medicine of Bratislava. This 
centre initially treated approximately 50 new patients per annum with 
this disease employing a multidisciplinary approach. Following this, 
there has been the establishment of similar specialist units in the 
largest hospitals in central and eastern Slovakia.
175. Plesko et al [45], using data available until 1990, demonstrated that 
whereas the incidence rate of testis cancer has gradually increased 
between 1968 and 1990, the mortality rate has declined slightly since 
the early 1980s following an initial increase between 1968 and 1980. 
The gap between incidence and mortality is increasing indicating 
increasingly efficacious therapy of patients with testicular cancer in 
Slovakia. The authors concluded that this gap is likely to grow as more 
recent data become available and this has been the case.
176. The economical development taking place in Slovakia and the 
coincident establishment of specialist treatment centres have appeared 
to contribute to the improved outcome of testicular cancer in Slovakia. 
In no country of central and eastern Europe was the economic change 
as rapid as in the former German Democratic Republic (DDR, 
commonly called East Germany). Mortality data from the former 
German Democratic Republic (GDR) has become available since 1980. 
In the former Federal Republic of Germany (FRG), the mortality rate of 
testicular cancer peaked around the mid-1970s and by 1995 the 
mortality rate (0.4 per 100,000) was less than one-third the mortality 
rate in 1977 (1.4 per 100,000), when details of treatment advances 
were published. In the former German Democratic Republic, the 
mortality rate remained essentially unchanged until the opening of the 
border in 1989 (1.5 per 100,000) and has subsequently declined by 
over fifty percent in the following years [46]. The most recent mortality 
rate (0.7 per 100,000) remains a little higher in the territories of former 
GDR than that in former FRG (0.4 per 100,000).
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177. The decline In mortality from testicular cancer In the former German 
Democratic Republic has paralleled the economic changes following 
German re-unification and provides further support to the hypothesis 
that economic considerations had previously limited the implementation 
of new treatment for this curable cancer. Unfortunately, this has 
caused at least 1000 deaths to occur since 1977 in this population 
which were avoidable [46].
178. In 2002, Levi et al [47] systematically considered trends in mortality 
from testicular cancer in Europe, the United States and Japan and, 
within Europe, in separate geographic areas and countries. In the 
European Union (EU), the peak rate (0.9/100,000 at all ages, 
1.6/100,000 at age 20 to 44) was reached in the early 1970's, and 
mortality has decreased thereafter by 63% at all ages and 67% at age 
20 to 44. In the six countries of central and eastern European providing 
data [to the World Health Organisation Mortality Database] the peak 
rate (0.9/100,000 at all ages, 1.9/100,000 at age 20 to 44) was 
reached in the late 1970's, but the declines have been much smaller 
thereafter (16% and 22%, respectively). In the United States, the peak 
(0.8 and 1.5) was even earlier, i.e., in the late 1960's, and testicular 
cancer rates have declined thereafter by over 70% both at all ages and 
at age 20 to 44, levelling around rates of 0.2/100,000 at all ages and 
0.4/100,000 at age 20 to 44 in 1995-97. In Japan, testicular cancer 
mortality rates have systematically been much lower than in other 
areas. Appreciable declines were however observed during the late 
1970's, to reach rates of 0.1/100,000 at all ages and 0.3/100,000 at 
age 20 to 44.
179. In 1975-79, the highest all age rates were in Denmark 
(1.7/100,000), Switzerland (1.5), Norway (1.3), Austria and the Czech 
Republic (1.2). The falls in rates were between 55 and 70% in most 
western European countries -  with the major exception of Spain and
71
Greece -  but comparatively smaller (25 to 30%) in the Czech Republic, 
Hungary and Poland. Mortality rates were upwards in Bulgaria and 
Romania. Consequently, in the late 1990's, the highest testicular cancer 
rates were in Bulgaria (1.0/100,000), the Czech Republic (0.9), 
Hungary (0.8) and Poland (0.7). The overall decline was 75% (from 0.8 
to 0.2/100,000) in the whole European Union. The fall was 53% in the 
USA, and 58% in Japan, which reached rates of 0.1-0.2/100,000 in the 
late 1990's. The pattern of trends was similar at age 20 to 44, when 
approximately half of the deaths from testicular cancer were reported, 
although absolute values were higher [47].
180. The incidence rates of testicular cancer are increasing almost 
everywhere for reasons that are not entirely clear: for example, over a 
60 year period incidence rose ten-fold in young men in Connecticut 
[48]. Hypotheses to be studied are complicated and exposure 
assessment is difficult. For a form of cancer which is increasing so 
much, there Is some degree of complacency in undertaking aetiological 
studies. One principal contributory reason is the potential complacency 
induced by the low and declining mortality rate.
181. From examination of observations on the outcome of testicular
cancer at population level, there are at least four main messages which
emerge [49]:
■ although platinum-based chemotherapy schemes have been available 
since the 1970% the fall in testicular cancer mortality has not been the 
same in various areas of the world.
■ there is some suggestion of a levelling off in the decline over the last
few years, both in the European Union and the United States of
America.
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« Within the European Union, the decline was proportionally smaller in 
Mediterranean countries, although absolute rates in the late 1990's 
were comparable to other European areas.
■ the delay in the fall in testicular cancer mortality has been substantial 
in central and eastern Europe, although a 20 to 30% fall was observed 
during the 1990's. In any case, many avoidable deaths per year are still 
registered in eastern Europe for a largely curable disease in young 
men.
182. Although national mortality data cannot directly address issues of 
equity, they indicate that in central and eastern Europe the persisting 
inadequacies in adopting adequate treatments remain widespread and 
substantial, and require urgent action. One of the major challenges 
today in Cancer Control is to implement the knowledge which is 
currently available regarding effective ways of preventing cancer 
deaths. The causes of the anomalous situation of testicular cancer 
mortality rates in central and eastern Europe should be identified with a 
high priority otherwise there shall continue to be several hundred 
preventable deaths occurring every year.
183. When the (United States) National Cancer Act was signed into law 
on 23^  ^ December 1971, what became widely known as the War 
Against Cancer was launched. At the time of this signing, testicular 
cancer was almost invariable fatal whereas today, in most developed 
countries, testicular cancer is almost always curable. This has been a 
major achievement for Cancer Control in the United States and similar 
countries.
184. Testicular cancer could become a very rare cause of death around 
the world if the knowledge currently available could be implemented 
world-wide. It is clear that when the economic situation makes the
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necessary drugs available, large reductions in mortality can occur quite 
rapidly. It is clear also than when treatment can be centralised, 
outcome also improves.
185. Testicular cancer could be almost eliminated as a cause of death 
world-wide. All that is required is the political will, adequate finance 
and the necessary training and logistics to deliver the most appropriate 
treatment. The package to eliminate testicular cancer death is 
resource-based rather than depending on the outcome of further 
research [49].
186. Eradication of testicular cancer death will not make a large impact 
on overall cancer mortality although it will have a large impact at ages 
up until 45, where testicular cancer is the most common cancer in men. 
However, it will provide an example of what can be done when an 
achievable target is identified and all necessary resources, both 
financial and logistical, are brought to bear in an organise manner. The 
aim of all cancer research should be to do something for the benefit of 
the patient with cancer or those who are at risk of developing the 
disease. Implementation of research findings to bring about Testicular 
Cancer Control would mark the finest illustration of this entire process 
so far [49].
5.2 Prostate Cancer
187. Prostate cancer continues to present perplexing problems from the 
epidemiological perspective. Continual examination of temporal trends 
has proven difficult from changes in the basis of diagnosis (which have 
strongly perturbed incidence statistics) to changes in coding the 
underlying cause of death.
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5.2.1 Prostate Cancer Trends until 1980
188. Prostate cancer has been poorly researched and understood from 
the epidemiological perspective. In the early 1980s, we undertook a 
systematic review of all existing incidence and mortality data [50].
189. These data demonstrated a 120-fold difference between the lowest 
and highest incidence rates of prostatic cancer, the disease being very 
common in North America, particularly among Blacks, and in 
Scandinavia, while it is rare in Japan and other oriental countries. The 
highest mortality for prostatic cancer is reported from St. Vincent and 
Grenadines, Martinique and Bermuda, from countries where the 
morbidity statistics are not available; the mortality rates reported from 
the United States and Canada are considerably lower. The incidence of 
and mortality from prostatic cancer have increased in most countries, 
in particular in areas with an initially low frequency of this disease. The 
ratio of mortality to incidence for prostatic cancer varies rather widely, 
being low in North America, Hawaii and Scandinavia.
190. We suggested that the observed variation in the mortality to 
incidence ratio for prostatic cancer could be due to differences in 
diagnostic practices between countries. This could explain, at least in 
part, the fact that the increasing trends of prostatic cancer incidence in 
North America are not accompanied by an increase in mortality from 
this tumour. This notion, however, does not exclude advances in 
treatment as possible determinants of the Improved survival rate from 
prostatic cancer in this part of the world [50].
191. The available statistics on prostatic cancer are based on the sum of 
clinically diagnosed carcinomas and those latent tumours found 
unexpectedly at prostatectomy and autopsy. The proportion of latent 
carcinomas among all prostatic cancer cases depends on the detection
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rate and varies from country to country, thus casting uncertainty on 
the comparability of prostatic cancer statistics from different areas. To 
avoid confusion in the statistics of prostatic cancer, it would be useful 
to consider introducing latent prostatic cancer as a separate entity in 
the next revision of the International Classification of Diseases (ICD) 
[50].
5.2.2 Prostate Cancer trends: an update
192. By 1990, in many countries of the world, prostate cancer is the 
second most common form of cancer in men, and in the United States 
it is now in first rank. It is an important public health problem, with 
more than 0.25 million new cases diagnosed worldwide in the year 
1985. Whereas earlier large increases in the incidence of prostate 
cancer were apparent throughout the world, the mortality rate has 
remained constant in generations of men born since the early years of 
this century. Most importantly, given that in several countries the 
increased number of children born after World War II will be in their 
mid-50s in the early part of the 21st century (at an age when cancer 
risk is becoming an important consideration), and coupled with the 
trends in increasing life expectancy, the consequence will be an 
increase in absolute terms in the number of cases of prostate cancer 
diagnosed. In the absence of treatment improvements and with 
prospects for prevention by modification of lifestyle remote within 
current knowledge, there will also be an increase in the number of 
deaths from prostate cancer worldwide. The situation would be further 
augmented by the presence of a temporal trend in risk that is widely 
reported from many countries and unlikely to be entirely artefact [51].
193. To help clarify the situation regarding the evolution of temporal 
trends, all national time series of prostate cancer mortality data 
available in the World Health Organisation (WHO) mortality database
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which fulfilled a series of conditions established a prio ri analysed 
in a systematic manner to investigate whether prostate cancer 
mortality was increasing and whether there were any striking 
similarities in the nature of any changes between countries. Age- 
Period-Cohort modelling was employed to establish and estimate the 
nature of any changes taking place [52].
194. In all datasets there is evidence of the presence of a cohort effect. 
Risk of prostate cancer increased among those born from the mid- 
1880s onwards until the cohort born around 1910. Subsequently in 
many countries the cohort-risk has remained constant although there 
were several notable exceptions such as Finland, Denmark and 
Czechoslovakia where the risk continues to increase. It is notable that 
the cohort relative risks for any cohort in any country are small and 
never exceed 1.5. While in many countries the all-ages mortality rate of 
prostate cancer appears to be continuing to increase, this is being 
driven by increasing rates among the oldest age groups which could be 
subject to the potential Influences of improvements in diagnosis and 
death certification [52].
195. Thus, based on an analysis of mortality data available until around 
1990, it could be expected that overall mortality rates from prostate 
cancer will soon begin to decline in many countries. The small changes 
in mortality rates in more recent cohorts of men (born since 1910 
onwards) contrast with the large increases seen in the incidence of 
prostate cancer and support the concept of an artificial inflation of 
incidence rates and a changing stage distribution brought about by 
aggressive histopathological examination of prostatectomy specimens 
(removed at TURP for benign prostatic hyperplasia) and the increasing 
use of prostate specific antigen (PSA) testing [52].
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196. Mortality from prostate cancer has increased throughout Europe 
until the early 1990s. Trends in 24 European countries, the European 
Union (EU), six selected Central and Eastern European countries, and 
the Russian Federation have been updated to 1999 using cancer death 
certification data for Prostate Cancer abstracted from the World Health 
Organization database [53].
197. In the European Union, the peak rate (15.7/100,000) was reached 
in 1993, followed by a levelling off and a decline to 14.1/100,000 in 
1999. Age-standardized analysis for each subsequent age group of men 
aged 50 or over showed larger absolute falls In the elderly. Prostate 
Cancer rates were lower in Central and Eastern European countries 
providing data, but showed a rise from 9.7/100,000 in 1980 to 11.3 in 
1996, and levelled off thereafter. Rates were originally lower, but the 
rises larger in the Russian Federation (from 5.1/100,000 in 1980 to 
8.1/100,000 in 1999). In the iate 1990s, there was a threefold 
difference between the highest rates of 22/100,000 in Norway and 
those of 7.7 in Russia or 7.3 in Ukraine. Such a difference was, 
however, restricted to the elderly, since at age 35-64 the Russian rate 
(6.7/100,000) was the same as that of Norway, and only Greece and 
Italy had appreciably lower rates.
198. The pattern of trends in Prostate Cancer rates observed across 
Europe is as previously predicted and is consistent with a favourable 
role of improved diagnosis, but mainly of advancements of therapy 
(including more widespread adoption of radical prostatectomy and 
androgen blockage) on Prostate Cancer mortality in Western Europe 
[53].
78
5.2.3 Aetiology of Prostate Cancer
199. In a review of all the available epidemiological evidence [54] it was 
apparent that there was nothing known with certainty about the 
environmental causes of prostate cancer. Prospects for prevention of 
prostate cancer were exceedingly poor. Two decades later, an updated 
review concluded that little progress had been made in the interim [55] 
despite several intriguing glimpses from epidemiological studies [56- 
57].
200. In collaboration with colleagues in Australia, notably Graham Giles 
and John Hopper, a major case-control study was undertaken in 
various centres in Australia incorporating collection of interview and 
biological data. This is the most sophisticated aetiological study of 
prostate cancer undertaken to date and could provide the most reliable 
information regarding the causes of prostate cancer.
5.2.3.1 Smoking and Prostate Cancer Risk
201. To examine the risk of smoking on histopathologically-confirmed 
moderate- and high-grade prostate cancer, a population-based case- 
control study was conducted in Melbourne, Sydney and Perth between 
1994 and 1998 in men aged below 70 years. Cases were recruited from 
cancer registries and controls were selected from electoral registers. 
1498 cases and 1434 controls were interviewed and a detailed smoking 
history obtained. Data were analyzed by unconditional logistic 
regression, adjusting for age, study centre, year of recruitment, family 
history and country of birth [58].
202. The odds ratios (OR) were 1.02 (0.85-1.22) for former smoking and 
0.82 (0.65-1.05) for current smoking. The respective ORs were 0.95 
(0.78-1.15) and 0.76 (0.59-0.99) for moderate grade tumours, and
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1.28 (0.96-1.70) and 1.00 (0.67-1.47) for high-grade tumours (P = 0.2 
for test that ORs of the two grades were identical). There was no 
evidence of a dose-response effect for duration of smoking, amount 
smoked daily, pack-years of smoking and years since quitting and most 
ORs for these variables were close to unity [58].
203. Smoking was not associated with the risk of prostate cancer. The 
widths and upper limits of the confidence intervals for the effects of 
current and former smoking were consistent with weak effects at most 
[58].
5.2.3.2 Early growth, adult body size and prostate cancer risk
204. The role of growth from birth through puberty and through adult 
life has been the subject of epidemiologic investigation in regard to the 
risk of prostate cancer but the evidence remains weak and inconsistent. 
We investigated associations between prostate cancer risk and a 
number of markers of body growth, size and changes to size in a 
population-based, case-control study in Australia from 1994 to 1998.
205. We analyzed data obtained in face-to-face interviews from 1,476 
cases and 1,409 controls. The main outcomes of interest were the 
timing of the growth spurt in adolescence, the experience of acne and 
interviewer observation of facial acne scarring, body size at age 21, 
body size in reference year, maximum body weight and rate of body 
size change since age 21 years. Analysis was performed on all cases 
and also by tumour grade [59].
206. We found no associations with measures of body size including 
body mass index and lean body mass at age 21 or later in adult life. 
Having a growth spurt later than friends reduced risk (odds ratio [OR] 
0.79 [0.63-0.97]) and some measures of acne also gave odds ratios
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less than 1, for example, having facial acne scarring gave an OR of 
0.67 (0.45-1.00) [59].
207. We conclude that markers of delayed androgen action, such as 
delayed growth spurt in puberty, and markers of other androgen- 
dependent activity in puberty, such as facial acne scarring, are 
associated with prostate cancer risk but we could detect no 
associations with markers of adult body size and growth including lean 
body mass.
5.2.3.3 Risk Factors for Androgenic Alopecia Risk
208. The epidemiology of androgenetic alopecia (AGA) is not fully 
understood. Although a strong genetic basis has long been identified, 
little is known of its non-genetic causes. To estimate the prevalence of 
and to determine risk factors for AGA in men aged 40-69 years in 
Australia, men (n = 1390) were recruited at random from the electoral 
rolls to serve as controls in a population-based case-control study of 
prostate cancer. All were interviewed in person and direct observations 
of AGA were made. Men were grouped into the following categories; no 
AGA, frontal AGA, vertex AGA and full AGA (frontal and vertex AGA). 
Epidemiological data collected from these men were used for an 
analysis of risk factors for each AGA category using unconditional 
logistic regression with AGA category as the response variable 
adjusting for age, education and country of birth.
209. The prevalence of vertex and full AGA increased with age from 31% 
(age 40-55 years) to 53% (age 65-69 years). Conversely, the 
proportion of men with only frontal AGA was very similar across all age 
groups (31-33%). No associations were found between pubertal 
growth spurt or acne, reports of adult body size at time of interview.
81
urinary symptom score, marital status, or current smoking status or 
duration of smoking and the risk of any form of AGA [60].
210. The consumption of alcohol was associated with a significant 
increase In risk of frontal and vertex AGA but not full AGA. Men with 
vertex AGA had fewer female sexual partners but average ejaculatory 
frequency did not differ between men in different AGA categories. 
Reported weight and lean body mass at reaching maturity at about 21 
years of age were negatively associated with vertex balding (P for 
trend < 0.05) but not with frontal AGA or full AGA [60].
211. Evidence for environmental influences on AGA remains very slight. 
Our study failed to confirm previously reported or hypothesized 
associations with smoking and benign prostatic hypertrophy. The 
associations that we found with alcohol consumption and with lean 
body mass at age 21 years would be worthy of further research if they 
were able to be replicated in other studies [60].
5.2.3.4 Androgenetic Alopecia and Prostate Cancer Risk
212. The purpose of this study was to examine the relationship between 
androgenetic alopecia (AA) and prostate cancer with particular 
emphasis on early age at diagnosis and higher grade tumors. We 
conducted an age-stratified, population-based case-control study in 
Australia of men who were diagnosed before 70 years of age during 
1994-1997 with histopathology-confirmed adenocarcinoma of the 
prostate, excluding well-differentiated tumors. Controls were selected 
from the electoral rolls, and the frequency was matched on age. After 
excluding subjects with missing values, the analysis was based on 1446 
cases and 1390 controls of whom direct observations were made of 
their pattern of AA during face-to-face interviews [61].
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213. Our data suggest an association between prostate cancer and 
vertex baldness; compared with men who had no balding, the adjusted 
odds ratio (OR) was 1.54 (1.19-2.00). No associations were found 
between prostate cancer and frontal baldness or when frontal baldness 
was present concurrently with vertex baldness. The ORs were 0.98 
(0.79-1.23) and 1.14 (0.90-1.45), respectively. The highest ORs were 
for high-grade disease in men 60-69 years of age: 1.80 (1.02-3.16) for 
frontal baldness; 2,91 (1.59-5.32) for vertex baldness; and 1.95 (1.10- 
3.45) for frontal and vertex baldness [61].
214. This association between the pattern of AA and prostate cancer 
points to shared androgen pathways that are worthy of additional 
investigation.
5.2.3.5 Foods, Nutrients and Prostate Cancer
215. A major hypothesis of this study was to examine the risk of prostate 
cancer associated with foods and nutrients, including individual fatty 
acids and carotenoids.
216. Population-based case-control study of 858 men aged <70 years at 
diagnosis with histologically confirmed prostate cancer of Gleason 
Grade 5 or greater, and 905 age-frequency-matched men, selected at 
random from the electoral rolls. Dietary intakes were assessed with a 
121-item food frequency questionnaire.
217. Inverse associations with prostate cancer were observed for (Odds 
ratio, OR, 95% confidence intervals, 95% Cl for fertile III compared 
with fertile I) allium vegetables 0.7, 0.5-0.9; p trend 0.01, tomato- 
based foods 0.8, 0.6-1.0; p trend 0.03 and total vegetables 0.7, 0.5- 
1.0; p trend 0.04. Margarine intake was positively associated with 
prostate cancer 1.3, 1.0-1.7; p trend 0.04. The only statistically
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significant associations observed with nutrients were weak inverse 
associations for palmitoleic acid ( p trend 0.04), fatty acid 17:1 ( p 
trend 0.04), and 20:5 n-6 ( p trend 0.05); and a non-significant trend 
for oleic acid ( p trend 0.09). Neither total, nor beverage-specific, 
intake of alcohol was associated with risk [62].
218. Based on these findings, diets rich in olive oil (a source of oleic 
acid), tomatoes and allium vegetables might reduce the risk of prostate 
cancer.
5.2.3.6 Sexual factors and prostate cancer
219. To assess whether prostate cancer might be related to hormone 
levels and, by inference, to differences in sexual activity, a case-control 
study of men with prostate cancer aged < 70 years at diagnosis and 
age-matched control subjects, information was collected on two 
aspects of sexual activity; the number of sexual partners and the 
frequency of total ejaculations during the third to fifth decades of life 
[63].
220. There was no association of prostate cancer with the number of 
sexual partners or with the maximum number of ejaculations in 24 h. 
There was a negative trend (P < 0.01) for the association between risk 
and number of ejaculations in the third decade, independent of those 
in the fourth or fifth. Men who averaged five or more ejaculations 
weekly in their 20s had an odds ratio (95% confidence interval) of 0.66 
(0.49-0.87) compared with those who ejaculated less often [63].
221. The null association with the number of sexual partners argues 
against infection as a cause of prostate cancer in this population. 
Ejaculatory frequency, especially in early adult life, is negatively 
associated with the risk of prostate cancer, and thus the molecular
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biological consequences of suppressed or diminished ejaculation are 
worthy of further research.
5.2.3.7 Circulating steroid hormones and the risk of prostate cancer
222. Although it is established that sex steroid hormones, particularly 
androgens, are essential to the growth, development and maintenance 
of healthy prostate epithelium, and to the progression of prostate 
cancer, epidemiological studies have failed to support the hypothesis 
that circulating androgens are positively associated with prostate 
cancer risk ("the androgen hypothesis") and some recent studies have 
even suggested that high testosterone (T) levels might be protective, 
particularly against aggressive cancer. This hypothesis could be tested 
by measuring total T, androstanediol glucuronide, androstenedione (A), 
dehydroepiandrostenedione sulfate (DHEAS), estradiol (E2) and sex 
hormone binding globulin (SHBG) in plasma collected at baseline in a 
prospective cohort study of 17,049 men.
223. We used a case-cohort design including 524 cases diagnosed during 
a mean 8.8 years follow-up and a randomly sampled sub-cohort of 
1,859 men. The association between each hormone level and prostate 
cancer risk was tested using Cox and competing risk models adjusted 
for country of birth.
224. None of the hormones was associated with overall or non- 
aggressive prostate cancer (all P for trend > 0.2). The hazard ratio 
(HR) (95% confidence interval) for aggressive cancer almost halved for 
a doubling of the concentration of T; HR 0.55 (0.32, 0.95) and A; HR 
0.51 (0.31, 0.83), and was 37% lower for a doubling of the 
concentration of DHEAS; HR 0.63 (0.46, 0.87). The dose-response 
relationship for free T was virtually identical to that for T. Similar 
negative but non-significant linear trends in risk for aggressive cancer
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were obtained for E2 and SHBG (P for trend = 0.2 and 0.1 
respectively).
225. High levels of T and adrenal androgens are, thus, associated with 
reduced risk of aggressive prostate cancer but not with non-aggressive 
disease.
5.2.3.8 ELAC2/HPC2 polymorphisms, prostate-specific antigen levels, and 
prostate cancer
226. This study, because of its advanced design, allowed detailed 
examination of genetic risk factors for prostate cancer. The ELAC2 
gene has been proposed to be a prostate cancer susceptibility gene 
and is being referred to as HPC2, in part because three case-control 
studies suggested that two common polymorphisms (Ser217Leu and 
Ala541Thr) are associated with risk. However, four subsequent larger 
studies have not confirmed this association. In five of the seven total 
studies, subject selection was influenced by prostate-specific antigen 
(PSA) levels. We examined the association and possible effect of 
subject selection in a larger study and a meta-analysis.
227. In a population-based study in Australia, 825 case patients and 732 
control subjects were genotyped for the Ser217Leu and Ala541Thr 
polymorphisms of ELAC2. Odds ratios (ORs) for prostate cancer were 
estimated by unconditional logistic and polytomous regression. A meta­
analysis was conducted combining our data with those from seven 
published studies. The association of genotype with the logarithm of 
plasma PSA levels in control subjects was analyzed by linear regression 
[65].
228. The ORs for prostate cancer were 0.74 (95% confidence interval 
[Cl] = 0.50 to 1.09) for Leu217 homozygotes and 1.01 (95% Cl = 0.68 
to 1.50) for Thr541 heterozygotes and homozygotes compared with
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Ser217 and Ala541 homozygotes, respectively. ORs were not changed 
by excluding control subjects with elevated PSA levels. Among control 
subjects, there were no statistically significant associations between 
genotype frequencies and PSA level for either polymorphism (both 
P>.4). The meta-analysis gave pooled OR estimates of 1.04 (95% Cl =
0.85 to 1.26) for Leu217 homozygotes and 1.18 (OR = 0.98 to 1.42) 
for Thr541 homozygotes and heterozygotes [65].
229. There is no evidence that either ELAC2 polymorphism is associated 
with prostate cancer or PSA level.
5.2.3.9 Polymorphisms in the prostate-specific antigen gene and prostate 
cancer risk and survival
230. The prostate-specific antigen {PSA) gene, also known as KLK3, is 
located on the long arm of chromosome 19 and encodes PSA that is 
widely used as diagnostic marker for prostate cancer. This gene 
contains several androgen responsive regions AREs. One of these AREs 
is located in the proximal promoter at -156 to -170 bp from the 
transcriptional start site of the gene and contains a polymorphic locus 
(rs266882) at -158 (A to G substitution) that was found to be 
associated with prostate cancer or circulating PSA levels in some 
studies but not in others, A recent study further characterized the PSA 
gene for polymorphisms and identified a sequence variation farther 
upstream of the PSA promoter at position -4643 (rs925013). This 
variant, a G to A substitution, was found to be associated with serum 
PSA levels and affected the functional activity of PSA promoter 
constructs. The hypothesis that the two variants rs266882 and 
rs925013 in the PSA gene are associated with circulating levels of PSA, 
prostate cancer risk and the risk of dying of the disease was tested 
using blood samples collected during a large population-based case- 
control study of prostate cancer.
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231. 821 prostate cancer cases and 734 controls were genotyped and in 
controls circulating levels of PSA were measured. Cases in the 
Melbourne arm of the study were followed-up to 31/12/2004 and 
deaths from prostate cancer ascertained. Linear regression of the log 
10-transformed PSA levels, unconditional logistic regression, Cox 
regression and haplotype analysis were used to test hypotheses.
232. No association was found between rs266882 and overall prostate 
cancer risk, survival and circulating PSA levels (all P > 0.1) but the risk 
of advanced-stage tumor was elevated in carriers of the G allele (OR 
1.5, 95% Cl 1.1 to 2.2, P = 0.02). The G allele in rs925013 was 
associated with an increased risk of prostate cancer (OR 1.4, 95% Cl
1.1 to 1.7, P = 0.001, dominant model). Men homozygous or 
heterozygous for the G/G haplotype (rs266882/rs925013) were at 
higher risk of prostate cancer than men homozygous for the A/A 
haplotype (OR 1.3, 95% Cl 1.1 to 1.6, 0.008 and OR 1.7, 95% Cl
1.1 to 2.4, P = 0.008 respectively, additive model). Although cases 
homozygous for the G allele in rs925013 were at higher risk of dying 
from the disease than cases homozygous for the A allele, the hazard 
ratio was not statistically significant (hazard ratio [HR] 2.3, 95% Cl =
1.0 to 5.6, P = 0.06, codominant model) and the overall tests for 
association between genotypes and survival were not significant (all P 
> 0.1). Adjusted geometric means of circulating PSA levels in controls 
were 1.2, 1.1 and 1.3 ng/ml for men with respectively zero, one and 
two copies of the G allele in rs266882 and 1.1, 1.2, and 1.5 ng/ml for 
men with respectively zero, one and two copies of the G allele in 
rs925013 (all P> 0.1).
233. The G variant in rs925013 and the G/G haplotype (rs266882/ 
rs925013) in the PSA gene were associated with increased prostate 
cancer risk. This study found only weak evidence that cases 
homozygous for the G allele in rs925013 had an increased risk of dying
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of the disease and little evidence of association between circulating PSA 
levels in controls and the two genetic variants.
5.2.4 Screening for Prostate Cancer
234. It is hard to imagine a single topic in cancer research at the present 
time which provokes so much polarisation of scientists and clinicians in 
the field as does prostate cancer. Particularly important questions 
revolve around the usefulness of early diagnosis and the treatment of 
early stage tumours. The prostate world is split between those who 
advocate that every man should be 'screened' and those who equally 
vehemently insist that no asymptomatic man should ever be screened 
and there is a need for evidence of effectiveness from scientific studies 
[67].
5.2.4.1 Prostate cancer mortality after introduction of prostate-specific 
antigen mass screening in the Federal State of Tyrol, Austria
235. To monitor the impact of screening in a natural experiment by 
comparing prostate cancer mortality in Tyrol, where prostate-specific 
antigen (PSA) testing was introduced at no charge, with the rest of 
Austria, where it was not introduced.
236. In 1993, PSA testing was made freely available to men aged 45 to 
75 years in the Federal State of Tyrol, Austria. At least two thirds of all 
men in this age range have been tested at least once during the first 5 
years of the study. Initially, only total PSA was measured, but free PSA 
measurement was added in 1995. The IMX assay was used. Digital 
rectal examination was not part of the screening examination [68].
237. Significant migration to lower stages has been observed since the 
introduction of this screening program. A reduction in mortality rates in 
the rest of Austria from 1993 onward has occurred, with the reduction
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in Tyrol much greater; the mortality remained fairly constant between 
1993 and 1995 and subsequently fell. The trends in prostate cancer 
mortality rates since 1993 differ significantly between Tyrol (P = 0.006) 
and the rest of Austria. On the basis of the age-specific death rates 
averaged from 1986 to 1990, the difference between the number of 
expected and observed deaths from prostate cancer in Tyrol was 22 in 
the group aged 40 to 79 years in 1998 and 18 the following year [68].
238. These findings are consistent with the hypothesis that the policy of 
making PSA testing freely available, and the wide acceptance by men in 
the population, is associated with a reduction in prostate cancer 
mortality in an area in which urology services and radiotherapy are 
available freely to all patients. It is our opinion that most of this decline 
is likely to be due to aggressive downstaging and successful treatment 
and that any contribution from detecting and treating early cancers will 
only become apparent in the years to come.
239. The situation in Tyrol continues to be monitored [69-70]. We have 
been able to update outcome information using mortality data from 
Tyrol and Austria until 2003 [70].Men with normal PSAs were invited to 
have a repeat test within a year while anyone with an elevated PSA 
was referred to their physician and then to a Urologist. The decision to 
perform biopsy was based on the age-specific PSA ranges, the percent 
free PSA and the transitional zone density. In all laboratories total PSA 
and percent free PSA concentration was assessed using the Abbott IMX 
assay. At the time of blood drawing no DRE was performed. In the first 
year alone, 32.3% of all men in this age group were tested and at least 
85% of all men in this age range have been tested at least once in the 
first ten years of the study.
90
240. Significant migration to lower stages and an increase in the number 
of organ-confined, potentially curable prostate cancers have been 
observed since the introduction of this screening programme. Mortality 
from prostate cancer among Austrian men aged 40-79 increased 
slightly from 1970 until 1992. No difference was noted in this trend 
between Tyrol and the rest of Austria (p=0.23). There has been a 
small but consistent reduction in prostate cancer mortality rates in the 
rest of Austria from 1993 onwards. The reduction in mortality rates in 
Tyrol has been much greater: mortality remained fairly constant 
between 1993 and 1995 and subsequently fell until 1999 and has 
subsequently achieved a plateau 20% lower than the rest of Austria. 
Trends in prostate cancer mortality rates since 1993 differ significantly 
between Tyrol (p = 0.0008) and the rest of Austria [70].
241. Although this is not a randomised trial but a description of the 
findings of a unique, natural experiment. These findings are consistent 
with the hypothesis that the policy of making PSA testing freely 
available, and the wide acceptance by men in the population, is 
associated with a reduction in prostate cancer mortality. This reduction 
appears to be approximately 25% which is similar to that achieved by a 
high-quality breast cancer screening programme [70].
5.2.4.2 Prostate Cancer Screening in Populations
242. Screening prostate cancer remains a highly controversial area 
between experts due to the lack of a clear evidence in the risk-benefit 
ratio: both screening and treatment of prostate cancer can be harmful 
making the trade off between benefits and risks, especially relevant. 
This deficiency in a proven clinical efficacy explains the varieties of 
contradictory recommendations from different organisations. In order 
to get a worldwide view of the different screening policies, a survey 
was conducted among the national delegates of the Internationale
91
Société dVroiogie, asking three very simple questions: (1) Is there a 
mass screening program for prostate cancer implemented in your 
country? (2) Is early detection for prostate cancer available in your 
country? (3) Is serum PSA test reimbursed in your country?
243. The survey revealed that no medical or health care organisation 
currently endorses mass screening for prostate cancer although 
Luxembourg is embarking on a national screening programme. This is 
due to the uncertainty regarding the efficacy of mass screening to 
decrease the specific mortality due to prostate cancer. However the 
lack of evidence does not prove there is no evidence to back up mass 
screening. To try to give a clear answer about the validity of mass 
screening several clinical studies have been undertaken.
244. The possible reduction in mortality due to screening, while 
uncertain, must be weighed against the substantial decrements in 
treatment-specific health outcomes among men treated for clinically 
localized tumours typically detected by screening. Concurrent with the 
successful life-saving efforts in terms of prostate cancer diagnosis and 
treatment, some men who do not need treatment are receiving it. 
These are men destined to die of causes other than prostate cancer.
245. Unfortunately, at diagnosis, men needing treatment for prostate 
cancer cannot be differentiated from men who do not. Unless the date 
of death from prostate cancer and the date of death from non-prostate 
cancer causes can be precisely determined for each patient, some men 
will always be over-treated or under-treated. Conservative strategies 
result in the under-treatment of some patients who would benefit from 
treatment while sparing other patients unneeded treatment. Aggressive 
strategies result in the over-treatment of patients who do not need 
therapy while curing other men of prostate cancer. Both strategies are 
correct, but only some of the time. Dramatic shifts in the incidence,
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grade, stage, and age of men with prostate cancer have been observed 
with the advent of widespread PSA-based cancer detection in the 
United States. Grade and stage trends suggest that more biologically 
relevant (the shift from well-differentiated to moderately differentiated 
tumours) and yet therapeutically amenable (earlier stage) tumours 
have been identified in large numbers of patients during the PSA era. 
Many men have been diagnosed and treated who will not benefit from 
such treatment. Given the long delay between treatment and mortality 
that is inherent in prostate cancer, the full effects of treatment on 
prostate cancer mortality are probably not yet seen in prostate cancer 
mortality data [71].
246. Population data and ongoing screening trials in the United States 
and Europe will be complementary in the final determination of the 
relative contribution of the impact of screening versus other causes on 
recent mortality trends. Unfortunately, it is not feasible for a physician 
to advise the patient requesting advice about PSA testing to return in 
4-6 years when the results of randomised trials will (probably) be 
available.
247. So what should be done and what should be recommended at the 
present time? Just imagine what the outcome of the much awaited 
randomised trials would be. If findings from both trials are positive in 
favour of PSA testing reducing prostate cancer mortality, then there 
would be an acceleration in the use of PSA testing and coverage of the 
population tested would grow.
248. But what would happen if both trials were to report null findings i.e. 
no reduction in prostate cancer mortality with PSA screening? It is 
highly likely that even if both trials are null, widespread PSA testing will 
continue to take place. There are several reasons for believing this. 
Trial results, pro and con, have been contentious issues among
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supporters and opponents of screening every since they were first 
undertaken. Specifically, we have recently witnessed the situation 
where the utility of mammographie screening for breast cancer has 
come under strong attack [69]. Even with data available from nine 
randomised trials of reasonable methodology, claims were made 
strongly that there was no evidence to support mammographie 
screening. With fewer trials available for evaluating prostate cancer 
screening, and with contamination rates in the control group likely to 
be very high, questions will be posed about the reliability of the 
findings.
249. Secondly, and importantly, the PSA test is straightforward, cheap, 
readily available and easily acceptable by the majority of men. PSA 
testing has already achieved a high penetration among men and their 
physicians. In 2000, in the United States it was estimated that
12,514,000 PSA tests were provided to the male population 
(135,000,000). Furthermore, PSA use among black and white Medicare 
beneficiaries older than 65 years during the calendar period from 
January 1991 through December 1998 was determined. PSA use 
stabilized among white men, reaching an annual rate of 38% by 1995 
and remaining at this level through 1998. The annual rate of use 
among black men reached 31% by 1998, but was still increasing at 
that time. By 1996, at least 80% of tests in both blacks and whites 
were second or later tests. By the end of 1996, 35% of white men and 
25% of black men were undergoing testing at least biannually or more 
frequently. In 1996, 83% of diagnoses in whites and 77% in blacks 
were preceded by a PSA test. In both race groups, an overwhelming 
majority of diagnoses are associated with a PSA test, whether for 
screening or diagnostic purposes [71].
250. An age-stratified population-based random digit dial (ROD) 
telephone survey determined prevalence of prostate-specific antigen
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(PSA) testing among Alberta men aged 40 74 years. The percentage of 
men who had ever had PSA testing was 4.5% at age 40-49, 13.1% at 
age 50-59, and 22.2% at age 60-74 years of age [72].
251. The extent of PSA testing outwith the North America is more 
surprising. For example, more than 2.2 million PSA tests were done on 
more than 1.1 miliion Australians between 1989 and 1996. The annual 
number of males tested increased fivefold in this period and peaked in
1995. Twenty-seven per cent of Australian men aged 50 years or over 
had at least one PSA test in 1995 or 1996; 33% of men aged 60-69 
years had a test in this period [38]. To document the extent of 
prostate-specific antigen (PSA)-testing in the general population at 
Getafe (Spain) a total of 5371 PSA-test records (1997-1999) were 
reviewed and testing rates estimated per 1000 person-years [40]. PSA- 
testing rate in the general population was 21.6/1000 person-years. In 
the age-group 55-69 years, this rate was 86.8/1000 and increased to 
152.6/1000 in men >70 years)[39]. In Milan, Italy where there is no 
campaign publicizing or encouraging prostate cancer screening, it has 
been estimated that 26.9% of men aged 40 and older and without a 
history of prostate cancer, received a PSA test in the two -year period 
1999-2000. In men aged 50 and greater, this rate rose to 34% [71].
5.2.4.3 Failure of Evidence-Based Urology
252. The degree of enthusiasm for prostate cancer screening seems high 
even given the limitations of the evidence of benefit and several 
reasons for this have been presented recently [71]. Given the current 
situation, there are several different strategies which could be 
introduced. For example, the (English) NHS Prostate Cancer Risk 
Management Plan recognises that an increasing number of men are 
sufficiently anxious about prostate cancer to seek help by asking for a 
PSA test. Under this plan any man considering a PSA test will be given
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detailed information to enable him to make an informed choice about 
whether to proceed with the test. Properly managed access to the PSA 
test has a significant part to play In empowering people to make 
decisions about their own lives. If, having had access to this 
information, any man who still wishes to have his PSA tested can have 
this provided for him by the NHS.
253. Multiple sources of data show that prostate cancer incidence rates 
rose following the introduction of PSA testing. The average age at 
diagnosis has fallen, the proportion of advanced stage tumours has 
declined, the proportion of moderately differentiated tumours has 
increased, and patterns of care have changed accordingly. A decline in 
mortality began in the United States and other countries in 1991. The 
decline in mortality is well established but this recent trend may only 
retrace an increase in mortality that immediately preceded this 
phenomenon. The descriptive epidemiology of prostate cancer reveals 
many effects of the introduction of prostate cancer screening. Although 
the evidence suggests increased prostate cancer testing has yielded 
public health benefit, this has not yet been shown conclusively [71].
254. The key centres around the adverse effects associated with radical 
treatment: could a moderate reduction in mortality be offset by a 
decreased quality-of-iife in men treated? Say, for arguments sake, one 
third of men diagnosed with prostate cancer die from the disease and, 
hence, in an unscreened population there are 1,000 prostate cancer 
deaths and 3,000 cases. If screening is introduced, decreases mortality 
by thirty per cent, then there should be 700 deaths. However, the 
incidence would double and there would be 6,000 prostate cancer 
cases, the majority of which would be early stage and suitable 
candidates for radical therapy. As mentioned above, in a random 
sample of Medicare patients the serious adverse effect rate was 28.6% 
in those treated radically. If 4,000 (out of 6,000) patients were treated
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radically, then it could be expected that there would be 1,114 serious 
adverse events. Preventing one death could result in serious adverse 
events in 2-3 men. The importance of having outstanding therapy in 
place for all men in any community screened is paramount [68, 71].
255. It is very unlikely that there will be any brakes put on the 
continually increasing use of PSA in the detection of Prostate Cancer in 
the years to come. It is quite possible to believe that it will become as 
widespread among men as cholesterol measurement and will share 
with that mode of screening the notorious distinction of never having 
had its value {m ortality reduction) demonstrated in a randomized trial. 
It is, however, an imperative duty, first of all, to ensure that the results 
of this natural experiment can be evaluated, and, secondly to seek 
ways to improve the outcome of therapy for prostate cancer. The 
adverse effects of radical therapy currently present the major hurdle in 
recommending mass screening for prostate cancer among populations. 
Systems should be in place right now to ensure that men and 
physicians participating in PSA testing should be participating in a 
programme in which the effect of the intervention can be evaluated. 
We owe this much to men in the community [71].
256. Whatever the arguments, the high penetrance of PSA testing in the 
male population around the world represents a colossal failure of the 
evidence-based approach to Policy formulation in Urology. The 
physician faced with a man asking about the advisability of having his 
PSA measured is now in a very difficult position. If he advises having 
the test performed the man runs the risk of having an adverse quality 
of life for no demonstrable gain in life expectancy. On the other hand if 
the physician advises against the test being performed, he (the 
physician) runs the risk of being confronted in five years time with the 
same man presenting with advanced (and fatal) prostate cancer. In 
large part, this dilemma has come about by the failure to respect the
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need for an evidence-based approach and the failure to impose the 
necessity of having such an evidence based approach.
